Protocol Number: RB244 -001 
Version 4.0; 07 JAN 2019  
  
 
Confidential |   Protocol: RB244 -001  | Version No : 4.0 Amendment | Date :  07 JAN 2019  Page 1 of 71 
 
 
 
CLINICAL STUDY PROTO COL  
A Vehicle- Controlled, Double -Blind, Randomized  Phase  II Study of B244 Delivered as a 
Topi[INVESTIGATOR_860749] D etermine Safety and Efficacy in Subjects with  Mild to Moderate 
Rosacea.  
Protocol Number : RB244 -001  
 VERSION 4.0 DATE :  07 JAN 2019  
 
Sponsor:  
AOBiome , LLC  
[ADDRESS_1199860]  
Cambridge, MA [ZIP_CODE]  
 
 
Any and all information presented in this document shall be treated as confidential and shall remain the 
exclusive property of AOBiome LLC (or any of its affiliated companies) .  The use of such confidential 
information must be restricted to the recipi[INVESTIGATOR_841] f or the agreed purpose and must not be disclosed, published or 
otherwise communicated to any unauthorized persons, for any reasons, in any form whatsoever without the prior written consent of AOBiome LLC (or the concerned affiliated company)
 

 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 3 of 71 
 
INVESTIGATOR SIGNATURE [CONTACT_860806]/her investigational site according to all 
stipulations of the protocol including all statements of confidentiality and in accordance with ICH GCP and local regulatory requi rements.  
Print Name   
[CONTACT_663231] / Site: __________________________________________________ 
__________________________________________________ 
__________________________________________________ 
__________________________________________________ 
Telephone Number:   
Investigator Signature : _______________________________ Date: _______________ 
  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 4 of 71 
 
PROTOCOL AMENDMENT 3  SUMMARY OF CHANGES  
Section  Description of Changes  
Synopsis  Added Exploratory Endpoint s: IGA t reatment success  
and CEA treatment success defined as “clear” or “almost 
clear” with a 2 -grade improvement in score from 
baseline to the end of treatment.  
Section 3 Study  Endpoints  Added Section 3.3 Exploratory Endpoint s: IGA 
treatment success  and CEA treatment success , defined 
as “clear” or “almost clear” with a 2 -grade improvement 
in score from baseline to the end of treatment.  
Section 14 Statistical Analysis  Added [IP_ADDRESS] Exploratory Endpoint s: IGA t reatment 
success  and CEA treatment success  defined as “clear” or 
“almost clear” with a 2 -grade improvement in score 
from baseline to the end of treatment.  
 
Administrative changes: Minor changes involving grammar, wordsmithing, punctuation, and other editorial changes hav e been made throughout the document .  All are clearly identified in 
the track -changes version of the amendment.  
 Additional formatting and stylistic adjustments h ave been made to facilitate the reading 
process.  
 
 
  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 5 of 71 
 
TABLE OF CONTENTS  
SIGNATURE [CONTACT_1783]  ............................................................................................................................................ 2 
INVESTIGATOR SIGNATU RE PAGE  ................................................................................................................... 3 
PROTOCOL AMENDMENT 3  SUMMARY OF CHANGES  ..................................................................................... 4 
TABLE OF CONTENTS  ....................................................................................................................................... 5 
GLOSSARY OF ABBREVIA TIONS  ....................................................................................................................... 9 
PROTOCOL SYNOPSIS  .................................................................................................................................... 11 
STUDY FLOWCHART  ...................................................................................................................................... 18 
SCHEDULE OF ACTIVITIES  .............................................................................................................................. 19 
PRINCIPAL CONTACTS  ................................................................................................................................... 21 
1 BACKGROUND AND RAT IONALE  ................................................................................................................. 22 
1.1 BACKGROUND  ................................................................................................................................................ 22 
1.2 RATIONALE OF THE STUDY  .................................................................................................................................  23 
1.2.1 Clinical Experience  .............................................................................................................................. 24 
1.2.2 Safety Profile  ....................................................................................................................................... 25 
2 STUDY OBJECTIVES  ..................................................................................................................................... 26 
2.1 STUDY OBJECTIVES  .......................................................................................................................................... 26 
2.1.1 Pr imary Objective  ................................................................................................................................ 26 
2.1.2 Exploratory Objectives  ........................................................................................................................ 26 
3 STUDY ENDPOINTS  ..................................................................................................................................... 26 
3.1 SAFETY & TOLERABILITY  .................................................................................................................................... [ADDRESS_1199861](S) .......................................................................................................... [ADDRESS_1199862] AT SITE ............................................................................................. 33 
6.5 TREATMENT ASSIGNMENT (RANDOMIZATION ) ...................................................................................................... 33 
6.6 BLINDING /UNBLINDING PROCEDURES  ................................................................................................................. 33 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199863] Informed Consent  ................................................................................................................. 39 
10.1.2 Documentation of Screen Failures  .................................................................................................... 39 
10.2  STUDY PROCEDURES  ...................................................................................................................................... 40 
10.2.1 Visit 1-  Screening Visit (Day - 21 to - 1) ............................................................................................... 40 
10.2.2 Washout Phase ( -14 to - 1) ................................................................................................................ 40 
10.2.3 Visit 2-  Baseline visit (Day 1):  ............................................................................................................ 40 
10.2.4 Visit 3-  Week 1 (Day 7) ±2 days  ........................................................................................................ 41 
10.2.5 Visit 4-  Week 4 (Day 28) ±2 days  ...................................................................................................... 41 
10.2.6 Visit 5-  Week 8 (Day 56) ±2 days  ...................................................................................................... 42 
10.2.7 Visit 6-  End of Study Visit -Week 12 (Day 84) ±[ADDRESS_1199864] Demographics  ...................................................................................................................... 43 
11.1.2 Medical history  .................................................................................................................................  44 
11.1.3 Concomitant Medication Recording  .................................................................................................  44 
11.1.4 Vital Signs  ......................................................................................................................................... 44 
11.1.5 Physical examination  ........................................................................................................................ 44 
11.1.6 Investigator’s Global Assessment (IGA)  ............................................................................................ 44 
11.1.7 Clinician’s Erythema Assessment (CEA)  ............................................................................................ 45 
11.1.8 Skindex  16 ......................................................................................................................................... 46 
11.1.9 Patient Self -Assessment (PSA)  .......................................................................................................... [ADDRESS_1199865]  .................................................................................................................................. 47 
11.2.3 Laboratory Assessments  ................................................................................................................... 47 
11.2.4 Biomarkers  ........................................................................................................................................ 48 
11.2.5 Samples Shipment  ............................................................................................................................. 48 
11.2.6 Treatment Adherence Evaluations  .................................................................................................... 48 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 7 of 71 
 
[IP_ADDRESS] Study Diary Compliance Review  ................................................................................................................. 48 
[IP_ADDRESS] Treatment Compliance  ............................................................................................................................... [ADDRESS_1199866] POPULATION /DATA SETS TO BE EVALUATED  .......................................................................................... [ADDRESS_1199867] Disposition and Demography  ............................................................................................... 54 
14.3.2 Assessment of Safety  ........................................................................................................................ 54 
14.3.3 Hypothesis Testing/ Assessment of Efficacy  ..................................................................................... 55 
[IP_ADDRESS] Exploratory Endpoints  ................................................................................................................................ 55 
14.3.4 Handling of Missing Values & Sensitivity Analysis  ............................................................................ [ADDRESS_1199868] (IRB)  / INDEPENDENT ETHICS COMMITTEE (IEC)  ...................................................... [ADDRESS_1199869] RETENTION  ...................................................................................................................................... 59 
17 PUBLICATIONS  ......................................................................................................................................... 60 
18 PROTOCOL ADHERENC E ........................................................................................................................... 60 
19 CLINICAL TRIAL PROTOCOL AMENDMENTS  .............................................................................................. 61 
20 PROPERTY RIGHTS  .................................................................................................................................... 61 
21 DATA PROTECTION  ................................................................................................................................... 61 
22 SPONSOR AUDITS AN D INSPECTIONS BY [CONTACT_860776]  ........................................................... 61 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 8 of 71 
 
22.1  QUALITY CONTROL (QC)  AND QUALITY ASSURANCE (QA) .................................................................................... 62 
22.1.1 Study Site Monitoring Visits  .............................................................................................................. 62 
22.1.2 Protocol Deviations  ........................................................................................................................... 62 
22.2  TRIAL DISCONTINUATION /INVESTIGATIVE SITE TERMINATION  ................................................................................ 63 
22.2.1 Criteria for Premature Termination or Suspension of the Study  ....................................................... 63 
22.2.2 Criteria for Premature Termination or Suspension of Investigational Sites  ...................................... 63 
22.2.3 Procedures for Premature Termination or Suspension of the Study or Investigational Site(s)  ......... 63 
23 REFERENCES  ............................................................................................................................................. 64 
24 APPENDICES  ............................................................................................................................................. 65 
APPENDIX 1: INVESTIGATOR GLOBAL ASSESSMENT (IGA)  ............................................................................................. 65 
APPENDIX 2: CLINICIAN ERYTHEMA ASSESSMENT (CEA)  ............................................................................................... 66 
APPENDIX 3: PATIENT SELF-ASSESSMENT (PSA) ......................................................................................................... 67 
APPENDIX 4:  SKINDEX 16 ...................................................................................................................................... 68 
APPENDIX 5: FITZPATRICK SKIN ASSESSMENT  ............................................................................................................. 70 
APPENDIX 6:  TELANGIECTASIA ASSESSMENT  .............................................................................................................. 71 
 
 
 
      
  
  
 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 9 of 71 
 
GLOSSARY OF ABBREVIATIONS  
ABBREVIATION  MEANING  
AE Adverse Event  
AOB  Ammonia -Oxidizing Bacteria  
BID Bis in Die (twice a day)  
BP Blood Pressure  
CEA  Clinician Erythema Assessment  
CRA  Clinical Research Associate  
CI Confidence Interval  
CRF  Case Report Form  
CTMF  Clinical Trial Master File  
CTP Clinical Trial Protocol  
eCRF  Electronic Case Report Form  
EOS  End of Study  
ET Early Termination  
ETR  Erythematotelangiectatic rosacea  
GCP  Good Clinical Practice  
IB Investigator’s Brochure  
ICH International Conference On Harmonization  
IEC Independent Ethics Committee  
IGA Investigator Global Assessment  
IGE Investigator’s Global Evaluation  
IP Investigational Product  
IPL Intense Pulsed L ight 
IRB Institutional Review Board  
ISF Investigator Site File  
IUD Intrauterine Device  
IUS Intrauterine system  
IWRS  Interactive Web Response System  
LOCF  Last Observation Carried Forward  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 10 of 71 
 
mITT  Modified Intent -To-Treat  
NSAID  Nonsteroidal Anti -inflammatory Drug  
OTC  Over the C ounter  
PP Per-Protocol  
PRN  Pro Re Nada  (as needed)  
PSA Patient Self -Assessment  
RR Relative Risk  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SI Simple Imputation  
SOP Standard Operating Procedures  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reactions  
TEAE  Treatment Emergent Adverse Event  
ULN  Upper Limit o f Normal Range  
UPT  Urine Pregnancy Test  
UV Ultraviolet  
WBC  White Blood Cell Count  
WOCBP  Women of Child Bearing Potential  
 
            
 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 11 of 71 
 
PROTOCOL SYNOPSIS  
TITLE:  A Vehicle -Controlled, Double -Blind, Randomized Phase  II 
Study of B244 Delivered as a Topi[INVESTIGATOR_860750].  
INVESTIGATIONAL 
PRODUCT  B244  
Topi[INVESTIGATOR_860751]  1. B244  
2. Vehicle  
PURPOSE:  The aim of the study is to assess the safety and efficacy of 
B244 in the treatment of  mild to moderate rosacea . 
STUDY OBJECTIVES:  Primary Objective:  
• To assess the safety and tolerability of B244 applied 
twice daily (BID) to the face for 8 weeks in subjects with mild to moderate  rosacea.  
Exploratory Objectives:   
To assess the efficacy of B244 in subjects with mild to 
moderate rosacea.  
• Proportion of subjects with IGA improvement at 
Week 8 relative to baseline 
• Proportion of subjects with CEA improvement at 
Week 8 relative to baseli ne 
• Change in IGA from Week 8 to Baseline  
• Change in CEA from Week 8 to Baseline  
• Proportion of Subjects with improvement in IGA  or 
CEA at Week 1, Week 4, and W eek 12.  
• Change in Skindex 16 patient reported outcome from 
Baseline to W eek 1 , Week 4, Week 8, and W eek 12.  
• Proportion of subjects with change in PSA at Week 1, 
Week 4, Week 8 and Week 12 from Baseline . 
• Evaluation of Telangiectasia Score at Baseline/Day1  
and Week 8  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 12 of 71 
 
STUDY DESIGN:  This is a Prospective, Vehicle  Controlled, Double Blind, 
Multicenter, Randomized Phase II trial, comparing the effect 
of twice daily B244 application for 8 weeks vs . vehicle 
application on treatment of mild to moderate rosacea.  
At Screening and Baseline:  
• All subjects must have  diagnos is of mild to 
moderate Rosacea.  
• Subjects must have IGA score of 2 -3 and CEA 
score of 2 -3 in order to qualify for the study.  
• After screening and recruitment, participants will 
be randomized to active or  vehicle application for 
8 weeks .  
• Subjects will apply  a total of 4 pumps  of IP  per 
application to  the face twice -a-day  
• Randomization will be 1:1 B244 to Vehicle.   
• Subjects will be provided with cleanser and 
moisturizer to use for the duration of the study  
• All B244 randomized subjects will be treated at the dose of 4x10
9 cells/ml via spray application  
• Screening period will occur at Days -21 to - 1  
• Washout will occur after Screening visit (Days -14 to - 1) 
• Randomization will occur d uring the baseline 
visit for the study  
• Efficacy will be assessed using Investi gator 
Global Assessment (IGA) score, Clinician’s 
Erythema Assessment (CEA) score, Patient Self -
Assessment (PSA) score and patient reported Skindex 16.  
• Clinical assessments of response to treatment will 
be made at  Week  1(Day 7 ), Week 4 (Day 28) , and 
Week 8 (Day 56)  
• At Baseline visit, s ubjects will receive a kit 
containing the drug product .  Each bottle will be 
used for [ADDRESS_1199870] to be used from Week 4 
through Week 8.    
• Subjects will stop applying investigational 
product  at Week [ADDRESS_1199871]  at that visit.  
• Subjects will come back for a 4- week  post-
treatment follow up visit at Week 12  (Day 84).  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 13 of 71 
 
• Participant's safety wi ll be monitored throughout 
the study .  Safety will be assessed by [CONTACT_860777], vital signs, clinical 
chemistry and hematology and overall tolerability 
of the investigational product .   
• Subjects would be  required to discontinue the 
investigational product  under the following 
circumstances:  
o Development of an intercurrent illness 
that would jeopardize the safety, or 
significantly affect assessments of clinical status of a subject  
o Either at the discretion of the Investigator 
or at the pa rticipant’s request 
o Development of any investigational 
product -related SAE  
o Suspected or laboratory -confirmed 
pregnancy  
STUDY POPULATION:  
 Inclusion Criteria  
In order to be eligible for the study, subjects must have 
fulfilled all of the following criteria.  
 
1. Male and female subjects ≥18.  
2. A clinical diagnosis of mild to moderate facial 
rosacea.  
3. In good general health as determined by a thorough 
medical history, physical examination, clinical 
chemistry and hematology.  
4. Presence of 3 to 20 inflammatory  lesions on the face 
(i.e. papules/pustules).  
5. A Clinician Erythema Assessment (CEA) scor e of 2 -
3 at Screening and at Baseline Visits (prior to the 
investigational product  application). 
6. Mild to Moderate IGA score of 2- 3 at Screening and 
at Basel ine Visits (prior to the investigational 
product  application).  
7. Willing to refrain from using any topi[INVESTIGATOR_860752], other than 
the investigational product. 
8. Females of childbearing potential with a negative 
urine p regnancy test (UPT) at Screening and 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 14 of 71 
 
Baseline/Day 1 (prior to the investigational product  
application) .  
9. Ability to comprehend and comply with study 
procedures.  
10. Agree to commit to participate in the current 
protocol. 
11. Provide written informed consent prior to any study 
procedure being performed.  
STUDY POPULATION:  
 Exclusion Criteria  
Any subject who me ets one or more of the following criteria 
is excluded from  this study :  
1. Female subjects who are pregnant , lactating or who 
are trying to conceive will be excluded from 
participation in this study.  
2. Any uncontrolled chronic or serious disease or 
medical condit ion that would normally prevent  
participation in a clinical trial, or, in the judgment of 
the Investigator, would put the subject at undue risk, or might confound the study assessments (e.g., other 
dermatological diseases), or might interfere with the 
subject’s participation in the study, (e.g., planned 
hospi[INVESTIGATOR_16366]).  
3. Particular forms of rosacea ( e.g., rosacea conglobata, 
rosacea fulminans, isolated rhinophyma, isolated 
pustulosis of the chin, Ocular rosacea Phymatous 
rosacea, Steroid -induced rosacea, severe rosacea 
including pyoderma faciale) or other concomitant 
facial dermatoses that are similar to rosacea such as peri-oral 
dermatitis, demodicidosis, facial keratosis 
pi[INVESTIGATOR_22785], seborrheic dermatitis, acute lupus 
erythematosus, or actinic telangiectasia.    
4. Presence of more  than two (2) nodulocystic lesions on 
the face.  
5. Presence of less than 3 and more than 20 inflammatory  
lesions  on the face (i.e. papules/pustules) . 
6. Severe papulopustular rosacea requiring systemic 
treatment . 
7. Participation at the time of eligibility assessment 
(Screening) in any other investigational   drug or 
device study or may have participated within 30 days 
prior to Screening .  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199872] remain unchanged throughout the study .  
Hormonal therapi[INVESTIGATOR_31430], but are not limited to, 
oral, injected or implanted hormonal methods of 
contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have c omparable efficacy 
(e.g. vaginal ring or transdermal hormone 
contraception)  
9. Presence of beard or excessive facial hair at Screening which  would interfere with the study  treatments or 
study assessments and refusal to remove for duration 
of study.    
10. Carcinoid, Pheochromocytoma or other systemic 
causes of flushing .  
11. Known s ensitivity to B244 or its components .  
12. Refusal to submit to blood and urine sampling for 
laboratory analysis.  
13. Treatment with the following:  
 
Prohibited Topi[INVESTIGATOR_577017]:  
Topi[INVESTIGATOR_860753]  2 days  
RHOFADE™ (oxymetazoline HCl) Cream, 1%  1 week  
Bleach baths  1 week  
Mirvaso (brimonidine) topi[INVESTIGATOR_68549]  1 week  
Vinegar  1 week  
Topi[INVESTIGATOR_860754]/OTC medications for 
treatment of acne  2 weeks  
Soolantra (Ivermectin 1%) topi[INVESTIGATOR_68549]  1 week  
Topi[INVESTIGATOR_745883]  2 weeks  
Use of over the counter antimicrobial  2 weeks  
Benzoyl Peroxide  2 weeks  
Immunomodulators  4 weeks  
Oracea (doxycycline) topi[INVESTIGATOR_68549]  2 weeks  
Corticosteroids  4 weeks  
Electrocoagulation, Dermabrasion; Facial peels  4 weeks  
Dermatologic/surgical procedure on the face  4 weeks  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 16 of 71 
 
Topi[INVESTIGATOR_860755] (e.g. azelaic acid, 
metronidazole, etc.)  [ADDRESS_1199873] (intense pulsed light) treatment  4 weeks  
Over the counter topi[INVESTIGATOR_684718]  4 weeks  
 
Prohibited Systemic Treatments:  
Systemic Treatment  Prohibited Time  Frame  prior to Baseline  
Exposed to excessive ultraviolet (UV) radiation 
and/or subject was unwilling to refrain from 
excessive exposure to UV radiation during the 
course of the study  1 week  
Prescription anti inflammatory  2 weeks  
Prescription/OTC anti-inflammatory 
medications (excludes low dose aspi[INVESTIGATOR_248])  2 weeks  
Systemic Antibiotics  4 weeks  
Systemic  medications for the treatment of 
rosacea (e.g. doxycycline, tetracycline, 
macrolides)  4 weeks  
 
Prescription medications for treatment of acne  4 weeks  
Corticosteroids (oral or injectable)  4 weeks  
Immunomodulators  12 weeks  
Oral retinoid use (e.g., isotretinoin), vitamin A 
supplements greater than 10,000 units/day  6 months  
 
STATISTICAL ANALYSIS : Analysis Populations:  
• Safety Population: The safety population includes 
all randomized subjects who received investigational 
product . 
• Modified Intent -to-Treat (mITT) Population: A 
modified intent -to-treat population includes all 
subjects who are randomized, applied at least one dose of assigned product, and returned for at least one post-baseline evaluation visit.  
• Per Protocol (PP) Population: The PP population 
includes all  randomized subjects who met all 
inclusion/exclusion criteria, were compliant with the assigned study treatment, returned to t he study site 
for the primary endpoint visit within the specified 
window (±2 days) OR discontinued from the study as 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199874] 50 % of IP, have at least one baseline and post 
baseline in clinic visit and did not have any major protocol violations.  
Efficacy Analysis:  
• IGA score at Baseline to Week 1, Week 4, Week 8 and 
Week 12  
• CEA score at Baseline to Week 1, Week 4, Week 8 and 
Week 12. 
• Skindex 16 patient reported outcome from Baseline to Week 1, Week 4, Week 8 and Week 12  
• PSA score at  Baseline to Week 1, Week 4, Week 8 and 
Week 12. 
Safety & Tolerability Analysis:  
Safety and tolerability endpoints will consist of all adverse events repor ted during the study duration. 
Exploratory Endpoint s: 
IGA t reatment success, defined as “clear” or “almost clear” 
with a 2 -grade improvement in IGA score from baseline to the 
end of treatment. 
CEA treatment success, defined as “clear” or “almost clear” 
with a 2 -grade improvement in CEA score from baseline to the 
end of treatment . 
   
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 18 of 71 
 
STUDY FLOWCHART  
Figure 1.  Study Flowchart  
 
STUDY SCHEMA  
 
 
 
 
  
             
            
  Male and Female subjects with clinical diagnosis of mild to 
moderate rosacea  
Randomized  
 
Vehicle  
Treatment  
Clinical Assessments at:  
Baseline, Weeks 1,4, 8 
 
End of Study visit/Clinical Assessment at Week 12  B244 
Treatment  Screening visit  
-21 to - 14 
Washout phase  
-14 to - 1 
Baseline visit 1  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 19 of 71 
 
SCHEDUL E OF ACTIVITIES   
Table 1: Schedul e of Study Activities  
 
 
 Visit Name  [CONTACT_213775]/  
DAY 1  Week 1  Week 4  Week 8  Week 12/ End 
of Study Visit  Early 
Termination 
Visit  
Visit number  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6   
Visit window in days  -21 to -1 1 7+/-2 28 +/ - 2 56 +/ - 2 84 +/ - 2  
Informed Consent  X       
Inclusion/Exclusion Criteria  X X      
Demographics  X       
Medical History  X X      
Concomitant Medications  X X X X X X X 
Physical Exam  X X    X X 
 BP & Pulse2 X X X X X X X 
Urine pregnancy test for WOCBP1 X X X X X X X 
Clinical chemistry and hematology and urinalysis3 X X  X X  X 
Biomarkers4  X   X  X 
CEA  X X X X X X X 
IGA X X X X X X X 
Skindex [ADDRESS_1199875] 5/[ADDRESS_1199876] from Subject5    X X  X 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199877] for more 
than 5 minutes sitting, then BP measurements and pulse (x3) will be performed, using the non -
dominant arm with a calibrated electronic sphygmomanome ter.  The average of the second and third 
readings will be documented.  
3. Subjects should fast for at least [ADDRESS_1199878] .  Laboratory work includes: hematology and Lipid 
Panel, Albumin, A lkaline Phos, ALT, AST, Total Bilirubin , BUN, BUN: Creatinine  ratio, Calcium, 
Chloride, Creatinine , eGFR, Glucose, Potassium, Sodium, Uric Acid, an d urinalysis .  HIV Ab, HCV Ab, 
HBsAg. will only be done at screening.  
4. Subjects should fast for at least [ADDRESS_1199879].  
8. Subjects will be asked to fill out study diary for the duration of the study . 
9. Cleanser and moisturizer will be dispensed at the Baseline visit.  Subjects will be asked to refrain, if 
possible, from using any other cleanser and/or moisturizer on their face and apply the provided product 
while they are participating in the trial.  Any left over moisturizer /cleanser will be collected  at Week 8 
visit, at which point subjects will be asked to go back to their regular routine.  
 
 Visit Name  [CONTACT_46702]  1 Week 4  Week 8  Week 12/End 
of Study Visit  Early 
Termination 
Visit  
Visit number  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6   
Visit window in days  -21 to - 1 1  7+/-2 28 +/ - 2 56 +/ - 2 84 +/ - [ADDRESS_1199880] Compliance5  X  X X  X 
Study Cleanser and moisturizer dispensation9  X  X    
Study Cleanser and moisturizer collection      X  X 
Study Diary8  X X X X  X 
Study Counseling7  X X X X   
AE Collection and Assessment  X X X X X X X 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199881] 
Inquiries  AOBiome  
Masha Gaber  
Clinical Operations  
[EMAIL_16291]  
Sponsor’s Medical Expert [INVESTIGATOR_860805] : Larry Weiss, MD  
Title : Chief Medical Officer  
Email: [EMAIL_16292]  
Reporting of Serious Adverse 
Events (SAEs) Biorasi Safety and Pharmacovigilance  
[ADDRESS_1199882]., Suite #900 
Aventura, FL [ZIP_CODE]  
Fax: +1 (786) 221- 3531  
RB244- [EMAIL_16293]  
 
 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199883] (between 2.7 and 10%) in 
patients with  northern European or Celtic heritage.[ADDRESS_1199884] classification system of rosacea subtypes 
based on the clinical characteristics .  The four basic stages of the disease are 
erythematotelangiectatic rosacea ( ETR ), papulopustular rosacea (PPR), phymatous rosacea, 
ocular rosacea and one variant rosacea, granulomatous rosacea (GR)  3.  
Diagnostic criteria of rosacea include primary features such as flushing , persistent central facial 
erythema, pustules , papules in the central facial distribution , thickened skin with irregular 
contours overlying the ears, cheeks, chin (gnathophyma), forehead (metophyma), and nose (rhinophyma) , watery, burning, dry, itchy, and light sensitive ocular sensation with a bloodshot 
appearance.
3 
Men are more prone to the phymatous skin changes associated with rosacea .  Rosacea patients 
experience periods of relapses and remissions .  There are trigger factors that can lead to a 
relapse such as: sun exposure, stress, hot weather, alcohol, spi[INVESTIGATOR_84716], exercise, wind, hot baths, cold weather, hot drinks and certain skin care products and medications.
[ADDRESS_1199885] not yet been fully elucidated .  However, t he pathology of rosacea may be multifactorial:  abnormal vascular and 
immune system responses; hair follicle  mite Demodex folliculorum and Demodex brevis ; 
bacteria such as H. pylori  and Bacillus oleronius ; prolonged steroid use and other aggravating 
trigger factors like sun and stress.
5,[ADDRESS_1199886] higher 
density  of Demodex mites on their skin compared to controls8,9. 
In addition, presence of Demodex mite on facial skin has also been associated with itching, 
with or without erythema10.  
Bacillus  bacteria found in the  Demodex mite stimulate immune response and produce an 
antigen that could be responsible for the tissue inflammation11.  
Epi[INVESTIGATOR_860756], therefore these ecto -parasites are found in the areas rich in sebaceous glands, such as the face, 
including cheeks, nose, chin and forehead12.  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199887] susceptible 
to rosacea changes, which in turn may produce higher density of bacteria and thus create an 
inflammatory response11.  
In the process of destroying epi[INVESTIGATOR_1663], Demodex penetrates  the dermis, stimulating Toll 
Like receptors (TLR)  leading to increased  skin inflammation and hyperreactivity to 
environmental stimuli.  
1.[ADDRESS_1199888]  in the 
Treatment of Mild -to-Moderate R osacea.  
There is no cure for rosacea and treatme nt is aimed at alleviating the symptoms.  Topi[INVESTIGATOR_860757].  These topi[INVESTIGATOR_860758]: metronidazole, azelaic acid, sodium sulfacetamide and sulfur, erythromycin, and tretinoin
8.  Currently these approved topi[INVESTIGATOR_860759] .  The oral medications prescribed for severe disease include tetracycline, 
doxycycline, minocycline, erythromycin and metronidazole .  The systemic therapi[INVESTIGATOR_66488] y 
result in systemic adverse events such as gastrointestinal upset and photosensitivity.  
It is believed, that topi[INVESTIGATOR_860760] -Oxidizing Bacteria ( AOB ) will reduce 
survival of pathogenic bacteria present on the skin and thus improve rosacea symptoms in those 
affected by [CONTACT_13114].  
AOBs are essential for the initial step in environmental nitrification processes, specifically the oxidation of ammonia (NH
3) to nitrite (NO 2-).  Nitrosomonas  are Gram -negative 
chemolithoautotrophic betaproteobacteria tha t obtain energy solely from NH 3 oxidation, while 
fixing CO 2 for their carbon needs13.  Oxidation of NH 3 proceeds in two steps ( Figure 2) leading 
to sequential generation of hydroxylamine (NH 2OH) and NO 2- that require two enzyme 
complexes: the membrane- bound ammonia monooxygenase (AMO) comprised of subunits 
AmoA, AmoB and AmoC; and the periplasmic NH 2OH oxidoreductase (HAO) .  In addition to 
high NO 2- levels, NH 3 oxidation leads to nitric oxide (NO) and N 2O production through two 
independent pathways downstream of NH 2OH production: nitrifier denitrification and NH 2OH 
oxidation14. 
  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199889] genetic profile from that of 
other published Nitrosomonas  strains and AOB genomes .  Based on in vitro  co-culture studies, 
B244 was able to reduce survival of pathogenic bacteria .  Nitrite generation from ammonia  
concurrently with medium acidification by B244 led to strong antibacterial effects and a marked reduction (~100- fold) in viable counts of methicillin -resistant Staphylcoccus aureus 
and Pseudomonas aeruginosa, two pathogens frequently isolated from infecte d skin and 
wound sites .  In contrast, control cultures with B244 in the absence of ammonium or with heat -
killed B244 supplemented with ammonium, had no antibacterial effects .  The unique metabolic 
and antimicrobial activity of Nitrosomonas , in combination with their lack of virulence render 
these bacteria as attractive candidates for topi[INVESTIGATOR_596867].  NO- releasing drugs or N O donors have also shown activity against Propi[INVESTIGATOR_860761], anti -inflammatory activity, and inhibition of lipogenesis 
by [CONTACT_134755] -stimulated immortal sebocytes
15, 16. 
 
1.2.1 Clinical Experience  
B244 is being developed as a ‘live topi[INVESTIGATOR_2855]’ to provide a natural source of AOB and NO/NO 2 
to the human skin.   A phase 1b/2a clinical trial entitled A Double Blind, Vehicle- Controlled, 
Single Center, Randomized, Sequential, Ascending 14- Day Multiple Dose Study in Subjects 
with Acn e Vulgaris to Evaluate the Safety, Tolerability and Preliminary Efficacy of B244 
Delivered as a Topi[INVESTIGATOR_860762] [ADDRESS_1199890] (IP) over [ADDRESS_1199891] been no 
attributable drug related SAEs reported.   In addition, a P hase 2b/3 clinical trial entitled A 
Randomized, Double Blinded, Phase IIb/III, Decentralized Study of B2 44 Delivered as a 
Topi[INVESTIGATOR_860763] 372 patients with clinical diagnosis of facial acne has been completed .  B244 was 
safe and well tolerated with no attributable drug rela ted SAEs .  Efficacy was supported by 
[CONTACT_596899] 2 -point reduction in IGA with B244 and a trend in the reduction of the 
number of inflammatory lesions compared to vehicle.  

 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 25 of 71 
 
Additionally, other topi[INVESTIGATOR_276905] B244 include hy pertension and atopic 
dermatitis .  A  study titled, “A Prospective, Controlled, Double Blinded, Multicenter, 
Randomized, Vehicle controlled, Phase II Study of B244 delivered as a topi[INVESTIGATOR_860764]” has been completed.  
Safety data indicated that B244 was safe and well tolerated .  Overall, 16% subjects experienced 
at least [ADDRESS_1199892] commonly reported types of events in the study were nervous sys tem disorders (5% 
incidence) and investigations (4% incidence) .  No TEAE was reported in more than [ADDRESS_1199893] 
in the B244 group.  There was no apparent increase in the incidence of TEAEs with increasing 
dose in either treatment group.  All TEAEs were Grade 1 or Grade 2 in severity .  There were 
no deaths in the study .  Overall, there were no unexpected safety signals observed following 
treatment with  B244.  
A study titled, “A Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized, 
Phase II Stud y of B244 Delivered as a Topi[INVESTIGATOR_860765]” is currently enrolling subjects .  
  
Furthermore,  a nasal spray of B244  is being developed  for treatment of allergic rhinitis and 
migraines .  A rat toxicology study performed by  [CONTACT_276938] B244 twice daily  
for 28 days found that B244 was safe and well tolerated in rats at levels of up to the maximum 
dose 8x109 cell/mL.   A study titled, “A P rospective, Controlled, Double Blinded, Single 
Center, Randomized, 3 arm, Phase 1b/2a  Study to Assess the S afety , Tolerability, and 
Preliminary E fficacy of B244 Delivered as an Intranasal S pray in Healthy V olunteers and 
Subjects with S easonal Allergic R hinitis ” has been initiated .  In addition, a study titled “A 
Prospective, Randomized, Vehicle -Controlled, Double -Blind, Phase 2 Study to Assess the 
Safety, Tolerability, and Efficacy of B244 Delivered as an Intranasal Spray for Preventive 
Treatment in Subjects with Epi[INVESTIGATOR_33185] ” is being initiated.  
 
1.2.[ADDRESS_1199894] 
heterotrophic bacteria, with optimum doubling times of 8 hours or higher.  In particular, Nitrosomonas  growth is rate limited by [CONTACT_276936] 
27 moles NH
3/mole CO 2 fixed.  Due to their dependence on ammonia for their growth, the 
numbers of Nitrosomonas  on the skin will be necessarily limited and naturally regulated by [CONTACT_860778] .  This would ensure that the amount of nitrite and NO 
generated would be relatively low, without any adverse effects.  
  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 26 of 71 
 
2 STUDY OBJECTIVES   
2.1 Study Objectives  
2.1.1 Primary  Objective 
• To assess the safety and tolerability  of B244 applied t wice daily (BID)  to the 
face for 8 weeks in subjects with mild to moderate rosacea.  
2.1.2 Exploratory  Objectives  
• To assess the efficacy of B244 in subjects with mild to moderate rosacea.  
o Proportion of subjects with IGA improvement at Week 8 relative to 
baseline.  
o Proportion of subjects with CEA improvement at Week 8 relative to baseline.  
o Change in IGA from Week 8 to Baseline .  
o Change in CEA from Week 8 to Baseline . 
o Proportion of Subjects wit h improvement in IGA or CEA at Week 1, 
Week 4, and W eek 12.  
o Change in Skindex 16 patient rep orted outcome from Baseline to Week 
1, Week 4, Week 8, and W eek 12. 
o Proportion of subjects with change in PSA at Week 1, Week 4, Week 8 and Week 12 from Baseline . 
o Evaluation of Telangiectasia Score at Baseline/Day 1 and Week 8  
 
3 STUDY  ENDPOINTS  
3.1 Safety & tolerability 
• Safety and tolerability endpoints will consist of all adverse events report ed during the 
study duration.  
3.2 Efficacy  
• IGA score at Baseline to Week 1, Week 4, Week 8 and Week 12 . 
• CEA score at Baseline to Week 1, Week 4, Week 8 and Week 12.  
• Skindex 16 patient reported outcome from Baseline to Week 1, Week 4, Week 8 and Week 12 . 
• PSA score at Baseline to Week 1, Week 4, Week 8 and Week 12.  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 27 of 71 
 
3.3 Exploratory  
• IGA t reatment success, defined as “clear” or “almost clear” with a 2- grade 
improvement in IGA score from baseline to the end of treatment.  
• CEA treatment success defined as “clear” or “almost clear” with a 2 -grade 
improvement in CEA score from baseline to the end of treatment . 
 
4 INVESTIGATIONAL PLAN  
4.1 Study Design  
• This is a Prospective, Vehicle Controlled, Double Blind, Multicent er, Randomized 
Phase II trial, C omparing the effect of twice daily B244 application for 8 weeks vs. 
vehicle application on treatment of mild to moderate rosacea.  
• We will enroll approximately  130 subjects and complete 104 subjects . 
• At Screening and Baseline:  
• All subjects must have  clinical diagnosis of mild to moderate rosacea . 
• Subjects must have IGA score of 2- 3 and CEA score of 2 -3 in order to qualify for 
the study.  
• After screening and recruitment, participants will be randomized to active or  vehicle 
application for 8 weeks .  
• Subjects will apply a total of 4 pumps  of IP  per application to  the face twice -a-day.  
• Randomization will be 1:1 B244 to Vehicle.   
• Subjects will be provided with c leanser and moisturizer to use for the duration of the 
study . 
• All B244 randomized subjects will be treated at the dose of 4x109 cells/ml via spray 
application . 
• Screeni ng will occur at Days -21 to - 1. 
• Washout will occur after Screening visit (Days - 14 to - 1). 
• Randomization will occur d uring the baseline vis it for the study ( Day 1) . 
• Efficacy will be assessed using Investigator Global Assessment (IGA) score, Clinician’s 
Erythema Assessment (CEA) score, Patient Self -Assessment (PSA) score and patient 
reported Skindex 16. 
• Clinical assessments of response to treatment will be made at  Week  1(Day 7 ), Week 4 
(Day 28) , and Week 8 (Day 56 ). 
• At Baseline visit, s ubjects will receive a kit containing the drug product .  Each bottle 
will be used for [ADDRESS_1199895] to be used from Week 4 through Week 8.    
• Subjects will stop applying investigational product  at Week [ADDRESS_1199896]  at that visit.  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 28 of 71 
 
• Subjects will come back for a 4- week  post-treatment follow up visit at Week 12  (Day 
84).  
• Participant's safety will be monitored throughout the study .  Safety will be assessed by 
[CONTACT_860779], vital signs, clinical chemistry and hematology and 
overall tolerability of the investigational product .   
• Subjects would be  required to discontinue the investigational product  under the 
followi ng circumstances:  
o Development of an intercurrent illness that would jeopardize the safety, or significantly affect assessments of clinical status of a subject  
o Either at the discretion of the Investigator or at the participant’s request  
o Development of any investigational product -related SAE  
o Suspected or laboratory -confirmed pregnancy  
4.2 Number of Subjects  and Sites  
Approximately 130 subjects are planned to be enrolled, and assuming a 20% drop out rate, the planned overall sample size for this clinical tr ial is approximately 104 adult male and female  
subjects,  18 years of age and older with mild to moderate  rosacea.  Subjects  will be randomized 
at a 1:1 ratio ( B244:  Vehicle) at about [ADDRESS_1199897] NONE of the following 
exclusion  criteria may be enrolled in the study:  
 
5.1.1 Inclusion Criteria  
1. Male and female subjects ≥18.  
2. A clinical diagnosis of mild to moderate facial rosacea.  
3. In good general health as determined by a thorough medical history, physical examination, clinical chemistry and hematology.  
4. Presence of 3 to 20 inflammatory  lesions on the face (i.e. papules/pustul es). 
5. A Clinician Erythema Assessment (CEA) score of 2- 3 at Screening and at Baseline 
Visits (prior to the investigational product  application). 
6. Mild to Moderate IGA score of 2 -3 at Screening and at Baseline Visits (prior to the 
investigational product  appl ication).  
7. Willing to refrain from using any topi[INVESTIGATOR_860766], other than the investigational product.  
8. Females of childbearing potential with a negative urine pregnancy test (UPT) at Screening and Baseline/Day 1 ( prior to the investigational product  application) .  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199898] at undue risk, or might confound the study assessments (e.g., other 
dermatological dise ases), or might interfere with the subject’s participation in the study, 
(e.g., planned hospi[INVESTIGATOR_16366]).  
3. Particular forms of rosacea ( e.g., rosacea conglobata, rosacea fulminans, isolated 
rhinophyma, isolated  pustulosis of the chin, Ocula r rosacea Phymatous rosacea, 
Steroid -induced rosacea, severe rosacea including pyoderma faciale) or other 
concomitant facial dermatoses that are similar to rosacea such as peri -oral dermatitis, 
demodicidosis, facial keratosis pi[INVESTIGATOR_22785], seborrheic dermatitis , acute lupus 
erythematosus, or actinic telangiectasia.    
4. Presence of more  than two (2) nodulocystic lesions on the face . 
5. Presence of less than 3 and more than 20 inflammatory  lesions on the face (i.e. 
papules/pustules) . 
6. Severe papulopustular rosacea requiring systemic treatment.  
7. Participation at the time of eligibility assessment (Screening) in any other 
investigational  drug or device study or may have participated within [ADDRESS_1199899] remain unchanged throughout the study .  
Hormonal therapi[INVESTIGATOR_31430], but are not limited to, oral, injected or implanted hormonal 
methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (e.g. vaginal ring or transdermal hormone contraception)  
9. Presence of beard or excessive facial hair at Screening which  would interfere with the 
study treatments or study assessments and refusal to remove for duration of study.    
10. Carcinoid, Pheochromocytoma or other systemic causes of flushing .  
11. Known s ensitivity  to B244 or its components .  
12. Refusal to submit to blood and urine sampling for laboratory analysis.  
13. Treatment with the following:  
 
Prohibited Topi[INVESTIGATOR_577017]:  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 30 of 71 
 
Topi[INVESTIGATOR_860753]  2 days  
RHOFADE™ (oxymetazoline HCl) Cream, 
1% 1 week  
Bleach baths  1 week  
Mirvaso (brimonidine) topi[INVESTIGATOR_68549]  1 week  
Vinegar  1 week  
Topi[INVESTIGATOR_860754]/OTC medications for 
treatment of acne  2 weeks  
Soolantra (Ivermectin 1%) topi[INVESTIGATOR_68549]  1 week  
Topi[INVESTIGATOR_745883]  2 weeks  
Use of over the counter antimicrobial  2 weeks  
Benzoyl Peroxide  2 weeks  
Immunomodulators  4 weeks  
Oracea (doxycycline) topi[INVESTIGATOR_68549]  2 weeks  
Corticosteroids  4 weeks  
Electrocoagulation, Dermabrasion; Facial 
peels  4 weeks  
Dermatologic/surgical procedure on the face  4 weeks  
Topi[INVESTIGATOR_860755] (e.g. azelaic acid, 
metronidazole, etc.)  [ADDRESS_1199900] (intense pulsed light) 
treatment  4 weeks  
Over the counter topi[INVESTIGATOR_860767] 4 weeks  
 
Prohibited Systemic Treatments:  
Systemic Treatment  Prohibited Time Frame  prior to Baseline  
Exposed to excessive ultraviolet (UV) 
radiation and/or subject was unwilling to 
refrain from excessive exposure to UV 
radiation during the course of the study  1 week  
Prescription anti inflammatory  2 weeks  
Prescription/OTC anti -inflammatory 
medications (excludes low dose aspi[INVESTIGATOR_248])  2 weeks  
Systemic Antibiotics  4 weeks  
Systemic  medications for the treatment of 
rosacea (e.g. doxycycline, tetracycline, 
macrolides)  4 weeks  
 
Prescription medications for treatment of 
acne 4 weeks  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 31 of 71 
 
Corticosteroids (oral or injectable)  4 weeks  
Immunomodulators  12 weeks  
Oral retinoid use (e.g., isotretinoin), vitamin 
A supplements greater than 10,000 units/day  [ADDRESS_1199901]’s safety .  Additional reasons for premature discontinuation of investigational product  
may inclu de adverse events and major non- compliance with study procedures , as described 
below .  The withdrawal of a subject  from investigational product  by [CONTACT_860780] , whenever 
possible. 
A subject will be discontinued from this study if any  of the following criteria are met:  
• Withdrawal of consent by [CONTACT_663193].  
• In the opi[INVESTIGATOR_689], Medical Monitor or Sponsor, it is not in the 
subject’s best i nterests to continue in the study.  
• Significant non -compliance with study procedures that would interfere with the study 
results or increase the subject’s risks in the study, as determined by [CONTACT_737].  
• Development of an intercurrent illness that would jeopardize the safety, or 
significantly affect assessments of clinical status of a subject.  
• Development of any investigational product -related SAE .  
• Suspected or laboratory -confirmed pregnancy . 
Subjects who discontinued early from the study due to lack  of treatment effect after completing 
at least four  weeks of treatment (Day 28) will be included in the mITT and PP population as 
treatment failures and the change in IGA and CEA from the baseline visit to the last completed 
visit prior to discontinuation due to lack of efficacy will be carried forward in the primary endpoint analysis. Subjects discontinued early for other reasons will be excluded from the PP population.  
5.[ADDRESS_1199902] discontinues prematurely, the Investigator will  perform Early Termination (ET) 
visit, capturing the reason for discontinuation.   
If a subject does not return for a scheduled visit, every effort will be made to contact [CONTACT_860781] .  The Investigator must document the primary 
reason for discontinuation of a study subject in the source document and on the appropriate 
electronic case report form (eCRF).  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199903](s)  
The term investigational product  is used to refer to the B244 and vehicle drug products .  Please 
see the study Pharmacy Manual  for full details.  
6.[ADDRESS_1199904] maintain study treatment 
accountability records throughout the course of the study .  The responsible person(s) will  
document the amount of study treatment  received from and returned to the Sponsor and the  
amount administered to participants .  The required accountability unit for this study will be  the 
bottle .  Discrepancies are to be reconciled or resolved.  
 
Product name:  B244, 30ml/bottle  Vehicle, 30ml/bo ttle 
Dosage form:  B244 suspension  Vehicle solution  
Unit dose strength:  4x109 cfu/ml  50nM Na 2HPO 4-2mM 
MgCl 2 (pH 7.6)  
Route/administration/duration:  Topi[INVESTIGATOR_860768] 8 weeks  Topi[INVESTIGATOR_860768] 8 weeks  
Dosing instruction:  4 pumps of spray to 
saturate the entire face applied BID .  
Applications should occur in  the morning and 
at night for 8  weeks.  4 pumps of spr ay to 
saturate the entire face applied BID .  
Applications should occur in  the morning and 
at night for 8  weeks.  
Physical descr iption:  Odorless, cloudy, light 
pi[INVESTIGATOR_276908], clear, and 
colorless s olution  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 33 of 71 
 
Manufacturer/source of 
procurement:  AOBiome, LLC  AOBiome, LLC  
6.[ADDRESS_1199905]’s kit .  The contents of the label will be in accordance with 
all applicable regulatory requirements .  B244 and matching vehicle will be packaged in 
identical [ADDRESS_1199906] at Site  
All investigational drug supplies in the study will be stored in a secure, refrigerated (2-8oC) 
safe place, under the responsibility of the Investigator or other authorized individual.  
The Investigator will maintain temperature monitoring of the investigational product  with daily 
temperature readings .  All temperature excursions must be reported to the Sponsor using the 
Temperature Excursion log .  If the investigational product  was exposed to the temperature 
excursion outside the range  of 2- 8oC, but for the period greater than [ADDRESS_1199907] be quarantined until the Sponsor’s approval on future use .  Please 
refer to the Pharmacy Manual  for additional detail on the Temperature Excursions and 
temperature monitoring during the shipment and storage at the site pharmacy.  
6.5 Treatm ent Assignment (Randomization)  
Randomization will be performed using an Interactive Web Response System (IWRS) at the 
time the subject has met all eligibility criteria and is ready for enrollment.  Subjects will be randomized in a 1:1 ratio to receive either B244 or vehicle  and will be stratified by [CONTACT_3725] . 
Interactive Web Response System (IWRS) will assign subjects to the treatment arm and specify the kit number to be dispensed.  
The randomization scheme will be generated and held by [CONTACT_860782] , Investigator, or 
study staff, or to clinical staff who could have an impact on the outcome of the study.  
6.6 Blinding /Unblinding Procedures  
This is a double -blind study, thus  Sponsor, CRO, site staff, study monitors, and subjects will 
be blinded to the randomization scheme .  The packaging of the investigational product  
products will be identical in appearance to make difference in treatment less obvious to the 
subjects.  
The b linding scheme for each set of the investigational product  will be available  to the FDA 
or other regulatory agency investigators at the time of site inspection to allow for verification 
of the treatment identity of each subject.  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199908] .  Unblinded information will be held 
by [CONTACT_394522](s), and the date and reason for breaking the blind must be recorded and reported appropriately to the IRB .  
 As the study is blinded, the Investigator should promptly document and explain to the Sponsor  
and Medical Monitor  any premature unblinding (e.g., accidental unblinding, unblinding due to 
a serious adverse event) of the investigational product(s).  
The Investigator may unblind a partici pant’s treatment assignment only in the case of 
emergency or in the event of a serious medical condition when knowledge of the study treatment is essential for the appropriate clinical management or welfare of the participant, as determined by [CONTACT_119576].  It is preferred (but not required) that the Investigator first 
contacts the M edical Monitor to discuss options before unblinding the participant’s treatment 
assignment .  The Investigator must notify the Sponsor as soon as possible when a participant ’s 
treatment assignment is unblinded without revealing the treatment assignment of the unblinded participant unless that information is deemed important for the safety of participants currently in the study .  The date and reason for the unblinding must be documented in the participant’s 
study record.  
The Investigator  may unblind the treatment assignment for any participant  with an SAE .  If the 
SAE requires that an expedited regulatory  report be sent to one or more regulatory agencies, a 
copy of the report, identifying the  participant ’s treatment assig nment, may be sent to clinical 
Investigators in accordance with  local regulations and/or Sponsor policy.  
6.[ADDRESS_1199909], such as excessive heat (temperatures over 77°F  (25°C) and freezing 
temperatures (at 0
oC).  Subjects may travel with their study medication but should not leave it 
in the hot car, outside in the cold temperatures etc.  Subjects will also be asked not to tamper or cause damage to investigational product  bottle . 
 Each subject will be instructed by [CONTACT_860783].  The 
following application instructions will be provided to the subject:  
• Subjects will apply [ADDRESS_1199910]  to saturate their face in the 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199911]  at night . 
• Subject should saturate the application area well.  
• Subjects will be asked to let the product air dry.  
• Subjects may not wash the ir face for [ADDRESS_1199912] .  
• Participants may not bathe, shower or wash their face until morning post evening 
application of IP . 
• While in use, one spray bottle may be st ored at ambient temperature .  The bottle that 
is not in current use by [CONTACT_423], must be stored in the refrigerator.   
• DO NOT FREEZE.  
6.[ADDRESS_1199913]  (deficient investigational product  in condition, appearance, pertaining documentation, 
labeling, expi[INVESTIGATOR_5695], etc.) should be promptly reported to the Sponsor, who will initiate a complaint procedure.  
All investigational product must be stored in a secure locked room with access limited to the 
Investiga tor and designated site personnel .  Study product is to be stored in a refrigerator 
between [ADDRESS_1199914] site Clinical Research Associate (CRA) or designee in case of any dispensing 
errors or if discrepancies are discovered.  
Prior to site closure and at appropriate intervals during the study, site CRA will perform investigational product  accountability and reconciliation .  At the end of the study, the 
Investigator will retain all the original documentation regarding investigational product  
accountability, return, and copi[INVESTIGATOR_245895]. 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199915] .  The I nvestigator will use  clinical 
judgment to treat any overdose.   
6.10 Dose Changes   
No dose changes are anticipated.  
 
7 CONTRACEPTION REQUIR EMENTS  
7.1 Contraception and Pregnancy Avoidance Measures  
Effective contraception is required  for all women of childbearing potential (WOCBP)  during 
study participation .  
Female subjects must be post -menopausal  OR surgically sterile or using highly effective birth 
control methods (note below) with a negative urine pregnancy test  at the Baseline Visit.  Male 
subjects must be willing to not attempt to conceive a child during the participation in the study.  
Acceptable forms of contraception include:  
Total abstinence; oral (birth control pi[INVESTIGATOR_3353]), intravaginal (e.g. NuvaRing®), implantable (e.g. 
Norplant®), injectable (e.g. Depo- Provera®) or transdermal (e.g. Ortho Evra®) contrace ption , 
intrauterine device (IUD) , double -barrier (diaphragm or condom with spermicidal gel or foam) 
for one month prior to study enrollment or a vasectomized partner ([ADDRESS_1199916] 
vasectomy).  
In case of use of oral contraception women should have b een stable on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_1199917] the 
Medical Monitor and the Sponsor .  Diligent efforts will be made to determine the outcome for 
all pregnancy exposures in the clinical trial .  Information on the status of the mother and the 
child will be forwarded to the Sponsor’s Safety Te am using the Pregnancy Data Collection 
Form .  Generally, follow -up will occur within 6 to 8 weeks following the estimated delivery 
date.  Any premature termination of the pregnancy will be reported.  Detailed guidance on the reporting of Pregnancies will b e provided in SAE and Pregnancy Reporting Guidance . 
Payment for all aspects of obstetrical care, child -or related care will be the study participant’s 
responsibility.  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 37 of 71 
 
8 CONCOMITANT MEDICATION S 
8.1 Prior , Concomitant and Prohibited Therapy  
Current medications and any medications taken within the 30 days prior to the start of the study 
will be recorded as prior/concomitant medications (using their generic name, if known) with 
the corresponding indication, start and stop dates .  The medications to be recorded include 
prescription, all over -the-counter (OTC) medications and all dietary supplements .  All 
medications taken on a regular basis should be recorded prior to commencing the use of the 
investigational product .  Any medications started during the study (including “as needed” 
medications) will be recorded in the concomitant medication list as soon as the Investigational Site will become aware of the medication being added.  
Prohibited Therapi[INVESTIGATOR_860769] [ADDRESS_1199918] of Prohibited Medication and Treatment Methods  
 
Prohibited Topi[INVESTIGATOR_577017]:  
Topi[INVESTIGATOR_860770]  2 days  
RHOFADE™ (oxymetazoline HCl) 
Cream, 1%  1 week  
Bleach baths  1 week  
Mirvaso (brimonidine) topi[INVESTIGATOR_68549]  1 week  
Vinegar  1 week  
Topi[INVESTIGATOR_860754]/OTC medications for 
treatment of acne  2 weeks  
Soolantra (Ivermectin 1%) topi[INVESTIGATOR_68549]  1 week  
Topi[INVESTIGATOR_745883]  2 weeks  
Use of over the counter antimicrobial  2 weeks  
Benzoyl Peroxide  2 weeks  
Immunomodulators  4 weeks  
Oracea (doxycycline) topi[INVESTIGATOR_68549]  2 weeks  
Corticosteroids  4 weeks  
Electrocoagulation, Dermabrasion; Facial 
peels  4 weeks  
Dermatologic/surgical procedure on the 
face 4 weeks  
Topi[INVESTIGATOR_860755] (e.g. azelaic acid, 
metronidazole, etc.)  4 weeks  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199919] (intense pulsed light) 
treatment  4 weeks  
Over the counter topi[INVESTIGATOR_860767]  4 weeks  
 
Prohibited Systemic Treatments:  
Systemic Treatment  Prohibited Time Frame  prior to Baseline  
Exposed to excessive ultraviolet (UV) 
radiation and/or subject was unwilling to 
refrain from excessive exposure to UV 
radiation during the course of the study  1 week  
Prescription anti inflammatory  2 weeks  
Prescription/OTC anti -inflammatory 
medications (excludes low dose aspi[INVESTIGATOR_248])  2 weeks  
Systemic Antibiotics  4 weeks  
Systemic  medications for the treatment of 
rosacea (e.g. doxycycline, tetracycline, 
macrolides)  4 weeks  
 
Prescription medications for treatment of 
acne 4 weeks  
Corticosteroids (oral or injectable)  4 weeks  
Immunomodulators  12 weeks  
Oral retinoid use (e.g., isotretinoin), vitamin 
A supplements greater than 10,000 units/day  [ADDRESS_1199920] (intense pulsed light) treatment  
laser peels or laser light therapy (including ThermaClear 
TM, blue light, tanning devices or 
photodynamic therapy ), steroid injections  throughout the study until the final follow -up visit.   
 If the Investigator becomes aware of a subject having taken a prohibited medication or 
performed prohibited procedure , they will report the incident to the Medical Monitor within 
24 hours, and the Medical Monitor and/or Sponsor will provide written approval of the subject’s continuation or discontinuat ion from the study.  
 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199921] should be advised t o apply it 10 minutes after the 
application of the IP.  
 
Subjects may use other cleanser s to wash other parts of their body not tre ated during the study .  
 At Week 8  (End of Investigational pr oduct  application) subjects will be asked to return cleanser  
and moisturizer that was  provided to them by [CONTACT_860784] . 
9.2 Use of makeup, moisturizers and sun screen  
• Use of anti -aging, anti -acne or rosacea treatment products or procedures on the face 
will be prohibited during the study.  
• Subjects  will be encouraged not to use other topi[INVESTIGATOR_860771], such as 
emollients, sunscreen, moisturizers, etc.  These should be used minimally or used 
sparingly while in the active phase (Baseline- Week 8) of the trial.  
• Participants will be advised to use minimally  or use sparingly liquid or powder makeup 
during the active phase (Baseline -Week 8) of the study.  
 
[ADDRESS_1199922] 
(IRB)/Independent Ethics Committee (IEC) and applicable regulatory authorities Informed Consent  Form must be obtained from each subject prior to performing any study related 
procedures .  No study related procedures or activities may be performed until each subject is 
fully informed and the consent form is signed and dated.  
10.1.[ADDRESS_1199923] Screening and Enrollment Log  capturing subjects screened and indicating who was 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199924] is f ound not to be eligible prior to 
enrollment, the reason(s) for ineligibility must be documented by [CONTACT_737] .  Subject 
Numbers assigned to subjects who fail screening will not be re -used.  
10.2 Study Procedures  
10.2.1 Visit 1 - Screening Visit (Day -21 to - 1) 
• Informed Consent  
• Inclusion/Exclusion Criteria  
• Demographics  
• Medical History  
• Concomitant and Prohibited Therapi[INVESTIGATOR_860772] 
• Physical examination  
• Collection of Vital Signs  
• Urine pregnancy test  for WOCBP  
• Venipuncture for Laboratory Assessment  & Urinalysis  
• Investigator’s Global Assessment [IGA]  
• Clinician’s Erythema Assessment [CEA]  
• Skindex -16 
• Patient Self -Assessment  (PSA)  
• Fitzpatrick skin type  
• Start AE collection and assessment  
 
10.2.2 Washout Phase ( -14 to - 1) 
Washout phase may be initiated after Screening procedures have been completed.  
 
10.2.3 Visit 2 - Baseline  visit (Day 1 ):  
Baseline visit will include the following procedures and  assessments:  
• Review of inclusion/exclusion criteria  
• Review of  Medical History  
• Concomitant and Prohibited Therapi[INVESTIGATOR_860772] 
• Physical examination  
• Collection of Vital Signs  
• Urine pregnancy test  for WOCBP  
• Venipuncture for Laboratory Assessment  & Urinalysis  
• Blood for biomarkers  
• Investigator’s Global Assessment [IGA]  
• Clinician’s Erythema  Assessment [CEA]  
• Skindex 16  
• Patient Self -Assessment  (PSA)  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 41 of 71 
 
• Telangiectasia Evaluation  
• Randomization  
• IP dispensation  
• IP compliance   
• IP application under medical supervision 
• Study cleanser and moisturizer dispensation 
• Study counseling 
• Study Diary  
• Adverse Even ts collection and assessment   
 
10.2.4 Visit 3 - Week 1 (Day 7) ±2 days  
The following procedures will be performed:  
• Concomitant and Prohibited Therapi[INVESTIGATOR_54482]  
• Collection of Vital Signs  
• Investigator’s Global Assessment [IGA]  
• Clinician’s Erythema Assessment [CEA]  
• Skindex 16  
• Patient Self -Assessment  (PSA)  
• Study Counseling 
• Study Diary  
• Urine pregnancy test  for WOCBP  
• Adverse Event collection and assessment  
 
10.2.5 Visit 4 - Week 4 (Day 28) ±2 days  
The following procedures will be performed:  
• Concomitant and Prohibited Therapi[INVESTIGATOR_54482]  
• Collection of Vital Signs  
• Venipuncture for Laboratory Assessment & Urinalysis  
• Investigator’s Global Assessment [IGA]  
• Clinician’s Erythema Assessment [CEA]  
• Skindex 16  
• Patient Self -Assessment  (PSA)  
• Urine pregnancy  test for WOCBP  
• Study cleanser and moisturizer dispensation 
• IP compliance   
• IP collection  
• IP dispensation  
• Study Counseling 
• Study Diary  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 42 of 71 
 
• Adverse event collection and assessment  
 
10.2.6 Visit 5 - Week 8 (Day 56) ±2 days  
The following procedures will be performed:  
• Concomitant and Prohibited Therapi[INVESTIGATOR_54482]  
• Collection of Vital Signs  
• Venipuncture for Laboratory Assessment  & Urinalysis  
• Blood for biomarkers  
• Investigator’s Global Assessment [IGA]  
• Clinician’s Erythema Assessment [CEA]  
• Skindex 16  
• Patient Self -Assessment  (PSA)  
• Telangiectasia Evaluation  
• Urine pregnancy test  for WOCBP  
• IP collection  
• IP compliance  
• Study cleanser and moisturizer collection  
• Study Counseling 
• Study Diary  
• Adverse event collection and assessment  
 
10.2.7 Visit 6 - End of Study Visit -Week 12  (Day 84) ±2 days  
The following procedures will be performed:  
• Concomitant and Prohibited Therapi[INVESTIGATOR_54482]  
• Physical Exam  
• Collection of Vital Signs  
• Urine Pregnancy Test for WOCBP  
• Investigator’s Global Assessment [IGA]  
• Clinician’s Erythema Assessment [CEA]  
• Skindex 16  
• Patient Self -Assessment  (PSA)  
• Adverse event collection and assessment  
 
10.2.[ADDRESS_1199925] to come in to the research center, subjects should be 
scheduled for the Unscheduled visit and assessments are performed based on investigator 
discretion . 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199926]’s 
condition will be considered as  worsening. 
 
10.2.9 Early Termination Visit  
Every attempt should be  made to complete all visits d uring the defined window periods .  
Subjects who do not complete all required study visits and withdraw from the study before 
Week 12 final visit, will be asked to complete the Early Termination Visit. 
 
During the visit, the following will be obtained:  
• Concomitant and Prohibited Therapi[INVESTIGATOR_54482]  
• Physical Exam  
• Collection of Vital Signs  
• Urine Pregnancy Test for WOCBP  
• Venipuncture for Laboratory Assessment & Urinalysis  
• Blood for biomarkers  
• Investigator’s Global Assessment [IGA]  
• Clinician’s Erythema Assessment [CEA]  
• Skindex 16  
• Patient Self -Assessment (PSA)  
• Telangiectasia Evaluation  
• IP collection  
• IP compliance  
• Study cleanser and moisturiz er collection  
• Study diary   
• Adverse event collection and assessment  
 
[ADDRESS_1199927] Demographics  
Basic demographic information, including date of birth, Fitzpatrick skin type  (classif ication of 
skin type (or phototype) depending  on the amount of  melanin  pi[INVESTIGATOR_860773]) , gender , 
ethnicity , and race will be recorded at the Screening Visit.  
 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199928] history of rosacea will be documented.  
 
11.1.3 Concomitant Medication Recording  
All medications (both prescription and nonprescription, and including vitamins, herbals, 
topi[INVESTIGATOR_8593], inhaled, and intranasal) taken within [ADDRESS_1199929]  and through the final study visit will be recorded on the appropriate eCRF (using their 
generic and brand name, if known) with the corresponding indication, start and stop dates .  At 
each study visit, subjects will be asked whether they have started or discontinued any medication since their previous study  visit.  This includes single use or PRN (as needed) 
medication use . 
Previous treatment of rosacea must be recorded irrespectively of the term it was given .  
Corresponding condition shall be captured i n the subject’s Medical History.  
 
11.1.[ADDRESS_1199930] should be asked to remove all 
clothing that covers the location of cuff placement .  The individual should be comfortably 
seated  in the chair , with the legs uncrossed, and the back and arm supported, such that the 
middle of the cuff on the upper arm is at the level of the right atrium (the mid -point of the 
sternum) .  Neither the subject  nor the obser ver should talk during the measurement .  After 5 
minutes sitting, serial clinic BP measurements and heart (x3) rate will be performed, using the 
non-dominant arm with a calibrated electronic sphygmomanometer .  The average of the second 
and third readings w ill be documented.  
Any abnormal characteristics will be evaluated by [CONTACT_860785].  Abnormal vital signs will be considered AEs if they require therapeutic medical intervention, and/or if the Investigator considers them to be AEs based on his/her clinical judge ment.  
 
11.1.5 Physical examination  
Physical examination, including height, weight, and evaluation of organs and systems (General Appearance, Heart/Cardiovascular, Lungs, Gastrointestinal, Ears / Nose / Throat, Extremit ies, 
and Skin) will be assessed at the Screening, Baseline and EO S/ET visits.  
Clinically significant abnormalities other than presence of rosacea lesions will disqualify subject from participation.  
 
11.1.6 Inves tigator’s Global Assessment (IGA ) 
An Inves tigator’s Global Assessment (IGA ) will be evaluated at each study visit ( Table 3 ).  
This scale should not be a reflection of treatment response, but should describe the condition 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 45 of 71 
 
at each visit .  Therefore, no reference should be made to baseline in the evaluation .  The 
Investigator will grade the severity of facial erythema, lesions, papules, pustules, and nodules  
from  0 to 4.  0=none, 1= almost clear , 2=mild, 3=moderate, 4=severe.   
 
Table 3.  Investigator’s  Global Assessment  (IGA) scale  
 
Score  Grade  Definition  
0 Clear  No inflammatory lesions present; at most, mild erythema  
[ADDRESS_1199931] Clear  Very mild erythema present .  Very few small papules/pustules  
2 Mild  Mild erythema .  Several small papules/pustules  
3 Moderate  Moderate erythema .  Several small or  large papules/pustules, and up to 2 
nodules  
4 Severe  Severe erythema .  Numerous small and/or large papules/pustules, up to 
several nodules  
Questionnaire can be found in Appendix 1 . 
 
11.1.7 Clinician’s Erythema Assessment (CEA)  
Clinician’s Erythema Assessment ( CEA ) will be will be evaluate d at each study visit .  The 
Investigator will assess the extent of rosacea based on the 5- point severity scale summarized 
below.  The Investigator will perform a static (“snap -shot”) evaluation of erythema severity using the 
CEA, and report  the one integer that best describes the overall severity  beginning from the 
Baseline Visit ( Table 4 ).  Although inflammation (papules, pustules, plaques) or dry 
appearance may  obscure the level of erythema, underlying redness should be evaluated 
disregarding this effect .  Inflammation or dry appearance may be noted, but perilesional 
erythema should not be included in this assessment .  Transient erythema (flushing) will also 
not be included.  
 Table  4.  Clinician Erythema Assessment  
 
Score  Severity  Description  
[ADDRESS_1199932] clear, slight redness  
2 Mild  Mild erythema; definite redness  
3 Moderate  Moderate erythema; marked redness  
4 Severe  Severe erythema; fiery redness  
Questionnaire can be found in Appendix  2. 
  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 46 of 71 
 
11.1.8 Skindex 16  
Skindex -16 instrument will be evaluate d at each study visit.  T he participant will answer a 
questionnaire examining the relationship between the patient’s skin health and quality of life.  
Skindex16 questionnaire can be found in Appendix  4. 
 
11.1.9 Patient Self -Assessment (PSA)  
Subjects will be asked to perform  static (“snap -shot”) evaluations of their rosacea -associated 
facial erythema severity using the Patient Self Assessment scale (PSA ) at each study visit, and 
report the one integer that best describes  the overall severity o f their facial redness as seen in 
a mirror at the time of the evaluation.  
 
Table 5 : Patient Self -Assessment  
 
Circle the number that best describes your rosacea -related facial redness RIGHT NOW . 
Score  Severity  Description  
0 No redness  Clear of unwanted redness  
1 Very mild  redness  Nearly clear of unwanted redness  
2 Mild  redness  Somewhat more redness than I prefer  
3 Moderate  redness  More redness than I prefer  
4 Severe  redness  Completely unacceptable redness  
Questionnaire can be found in Appendix 3 . 
 
11.1.10 Telangiectasia Evaluation  
Telangiectasia evaluation will be performed  at Baseline and Week 8 visit  as indicated in the 
Schedule of  Study Activities .  The Investigator will assess the extent o f telangiectasia  based 
on the 4- point severity scale summarized below.  
The Investigator will perform a static (“sn ap-shot”) evaluation of telangiectasia severity using 
the below scoring system.  
 Table 6: Telangiectasia Evaluation  
Score  Grade  Definition  
0 Clear  No telangiectasia  
1 Mild  Only few fine vessels discernible, involves 10% or less of the 
facial area  
2 Moderate  Multiple fine vessels and/or few large vessels discernible, 
involves > 10% - 30% of the facial area  
3 Severe  Many fine vessels and/or large vessels discernable, involves > 
30% of the facial area  
Questionnaire can be found in Appendix 6 . 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 47 of 71 
 
11.2 Safety Assessments  
11.2.1 Assessment of Adverse Events  
Beginning with the screening visit and through the EO S/ET visit, the Investigator and study 
personnel will review each subject’s clinical evaluation findings and query the subject directly 
regarding AEs (see Section 12, Safety Data Collection, Recording and Reporting). Subjects 
must be followed for AEs until [ADDRESS_1199933], Total 
Bilirubin , BUN, BUN:Creati nine ratio, Calcium,  Chloride, Creati nine, eGFR, Glucose, 
Potassium, Sodium, Uric Acid . 
Lipid Panel: HDL Cholesterol, LDL cholesterol, Total Cholesterol, Triglycerides, VLDL Cholesterol, LDL/HDL Cholesterol Ratio, Non HDL Cholesterol. Hematology: WBC, RBC, Hemoglobin, Hematocrit, Platelets, WBC Differential (Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils), HbA1C . 
Serology will only be done at Screening: HIV Ab, HCV Ab, HBsAg.  
Urinalysis will be perfor med according to the Schedule of Study Activities.  
 Patients will be asked to fast for at least [ADDRESS_1199934] will NOT be allowed into the study.  
 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 48 of 71 
 
11.2.4 Biomarkers  
In addition to the blood drawn for the safety laboratory asses sments, additional blood will be 
collected for the biomarker analysis at the times indicated in the  Schedule of Activities .  
Samples will be processed on site and aliquots stored in the - 80○ C freezer . 
Approximately [ADDRESS_1199935] 8 hrs.  before blood for biomarkers is drawn.  
Biomarkers will be evaluated for cytokines, chemokines, inflammatory markers and immune 
response.  
 
11.2.5 Samples Shipment  
All clinical chemistry samples are to be shipped to the central laboratory where samples will 
be analyzed.  
Biomarker samples  are to be shipped frozen monthly on dry ice to the central laboratory.  
Shipments should be made only on Mondays and Tuesdays to ensure receipt of the specimens by [CONTACT_52385].  
 
11.2.6 Treatment Adherence Evaluations  
[IP_ADDRESS] Study Diary Compliance Review  
The subject will be given a Study Diary at each study visit of the treatment period to record date and time of applications, any adverse events, quality of life assessments, of the 
investigational product .  Subjects will record every application during the treatment period and 
will bring the Subject Diary to each of the post -baseline study visits for compliance review .  
The Investigator wi ll verify that the subject complied with the application requirements and 
will file the completed Subject Diary in the study files at each study visit until the EOT/ET visit.  Any missed application notations will be clarified with the subject and document ed in 
the subject’s CRF.  
 
[IP_ADDRESS] Treatment Compliance  
Each site participating in the trial will be instructed to assess subject’s compliance by [CONTACT_860786] s in grams pre - and post-
application .  Study personnel will be asked to take out the bottles from the carton, weigh both 
bottle s and record the weight pre -first application .  At the Day [ADDRESS_1199936] measurements into the eCRF.  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199937] any Adverse Event ( AE) 
in detail including the date of onset, description, severity, time course, duration and outcome, relationship of the adverse event to investigational product , an alternate etiology for events not 
considered “related” or “probably related” to investigational product , final diagnosis, if known, 
and any action(s) taken. For AEs to be considered intermittent, the events must be of similar nature and severity and each intermittent AE will be reported separ ately .  AEs and SAEs, 
whether in response to a query, observed by [CONTACT_8786], or reported spontaneously by [CONTACT_41614], monitored and followed- up until the resolution (or until the 
Investigator deems the event to be stable/chronic). 
12.[ADDRESS_1199938] a causal relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the investigational product.  
Such an event can result from use of the drug as stipulated in the protocol or labeling, as well as from accidental or intentional overdose, drug abuse, or drug withdrawal .  Any worsening of 
a pre- existing condition or illness is considered an AE .  If a new rosacea signs or symptom or 
worsening of a rosacea sign or symptom was believed by [CONTACT_860787], then it will be  recorded as an AE .  Clinically 
significant abnormalities are to be followed to resolution (i.e. , become stable, return to normal, 
return to baseline, or become explainable) .  Laboratory abnormalities and changes in vital signs 
are considered to be AEs only if they necessitate therapeutic  medical intervention, and/or if the 
Investigator considers them to be AEs.  
 
12.1.2 Serious Adverse Events  
If an AE meets any of the following criteria, it is to be reported to the Sponsor’s Safety department and Pharmacovigilance as a S erious A dverse E vent (SAE) using SAE report form 
within 24 hours of occurrence or notification to the study site:  
 
Death of Subject  An event that results in the death of a subject.  
Life-Threatening  An event that, in the opi[INVESTIGATOR_689], would have 
resulted in immediate fatality if medical intervention had not been 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199939]'s hospi[INVESTIGATOR_4408].  
Congenital 
Anomaly/birth defect  An anomaly detected at or after birth or any anomaly that result 
in fetal loss.  
Persistent or 
Significant 
Disability/Incapacity  An event that results in a condition that substantially interferes 
with the activities of daily living of a study subject.  Disability is not intended to include experiences of relatively minor medical 
significance such as headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g ., sprained ankle). 
Other Important 
Medical Event  An important medical event that may not be immediately life -
threatening or result in death or hospi[INVESTIGATOR_059], but based on 
medical judgment may jeopardize the subject and may require 
medical or surgical intervention to prevent any of the outcomes listed above (i.e., death of subject, life - threatening, 
hospi[INVESTIGATOR_059], prolongation of hospi[INVESTIGATOR_059], congenital 
anomaly, or persistent or significant disability/incapacity) .  
Examples of such events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient 
hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
12.2 Adverse Event Severity  
The Investigator will use the following definitions to rate the severity of each AE and SAE:  
Mild  The event is transient and easily tolerated by [CONTACT_423].  
Moderate  The event causes the subject discomfort and interrupts the subject's 
usual activities.  
Severe  The event causes considerable interference with the subject's usual activities and may be incapacitating or life -threatening.  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 51 of 71 
 
12.3 Causality of Adverse Events  
The Investigator will use the following definitions to assess the relationship of the AE/SAE 
to the use of investigational product:  
Related  The event occurred within a reasonable time after drug administration 
or drug concentration and body fluids demonstrated that the 
investigational product  was present: the event could not be reasonably 
explained by [CONTACT_860788][INVESTIGATOR_014]; the adverse event abated after discontinuing the investigational product . 
Probably Related  The event has a strong temporal relationship to investigational product  
or recurs on re -challenge and another etiology is unlikely or 
significantly less likely.  
Possibly Related  The event has a strong temporal relationship to the investigational product  and an alternative etiology is equally or less li kely compared 
to the potential relationship to investigational product . 
Probabl y Not 
Related  The event has little or no temporal relationship to the investigational product  and/or a more likely alternative etiology exists.  
Not Related  The event is due to an underlying or concurrent illness or effect of 
another drug and is not related to the investigational product  (e.g., has 
no temporal relationship to investigational product  or has a much more 
likely alternative etiology).  
If an Investigator's opi[INVESTIGATOR_147530], probably not, or not related to investigational product  
is given, an alternate etiology must be provided by [CONTACT_663213]. 
12.4 Adverse Event Collection Period  
Adverse Event Collection Period starts with the Screening  visit once t he ICF has been signed 
through the follow -up visit (week 12) .  Any AE/SAE prior to the Screening  visit will be 
considered past medical history (PMH).  
SAE(s) that are observed or spontaneously reported during the subject’s participation in the trial will be captured and monitored until the Investigator deems the event to be chronic or not clinically significant or the subject to be stable.  
12.[ADDRESS_1199940] the minimum criteria (Site and Subject ID, Date site became aware of the event, S AE Term, Seriousness 
criteria, investigational product , Investigator/Reporter and site address) within 24 hours by 
[CONTACT_6968], fax, or telephone to the Sponsor’s Safety and Pharmacovigilance team. Sponsor’s Safety 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 52 of 71 
 
and Pharmacovigilance team will complete the SAE report for further evaluation and review 
by [CONTACT_860789] .  
Copi[INVESTIGATOR_860774]  (i.e., queries, medical 
records, lab records, IRB/IEC communications and all source documents) will be kept in the 
site’s study file.  
 
Primary Contact  [CONTACT_1378]/SAE Reports and Queries  
Email: RB244 -01-safet [EMAIL_16294]  
Medical Monitor:  [CONTACT_860807]: [EMAIL_8797]  
Phone: [ADDRESS_1199941] notes, and the monitoring 
site visit report.  In the event of an emergency necessitating unblinding the PI/site staff will make every effort to contact [CONTACT_860790]. 
Treatment assignment for an individual subject should be unblinded only in an emergency by 
[CONTACT_737], when knowledge of the treatment assignment is urgently nee ded for the 
clinical management or welfare of the subject .  Treatment should be provided in accordance 
with the medical condition and with regard to the information provided in the Investigator’s Brochure.  
According to the FDA guidance Safety Assessment fo r IND Safety Reporting IND safety 
reports submitted should be unblinded.  If the blind is broken and a subject with an adverse 
event that would meet the criteria for reporting as a single event was receiving vehicle, the event will not be reported in an IND safety report because there is a reasonable possibility that the drug di d not cause the adverse event but in the event of an SAE determined to be as a result 
of drug exposure reporting to the FDA will take place.  
The Investigator must document the breaking of the code, and the reasons for doing so on the eCRF, in the site file, and in the medical notes.  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199942] notify the IRB and the Sponsor in writing as soon as possible following 
the code break detailing the necessity of the code break , all other members of the research team 
should remain blinded. 
14 DATA ANALYSIS  
The data analys is will be conducted on all participant data when the trial ends.  Data will be 
presented by [CONTACT_6654].   
Categorical variables will be summarized by [CONTACT_119395] (number and percentages 
of subjects) and cont inuous variables will be summarized by [CONTACT_9086] (mean, 
standard deviation, etc. ). 
Adverse events will be summarized by [CONTACT_860791] (MedDRA) system organ class and preferred term .  Sep arate tabulations 
will be produced for all treatment -emergent AEs (TEAEs), treatment -related AEs (those 
considered by [CONTACT_192158]), SAEs, discontinuations due to AEs, and AEs ≥Grade [ADDRESS_1199943] listings will be provided for any deaths, SAEs, 
and AEs leading to discontinuation. 
Descriptive statistics for each treatment group will be provided for clinical laboratory values 
(e.g., hematology, serum chemistry, and urinalysis) and vital signs data, presented as both 
actual values and changes from baseline relative to each on -study evaluation.  Abnormal 
clinical laboratory values will be listed.  
All data will be provided in by -subject listings.  
14.[ADDRESS_1199944] Population/Data Sets to Be Evaluated 
The subject populations are defined as follows:  
• Safety Population: The safety population includes all randomized subjects who 
received investigational product . 
• Modified Intent -to-Treat (mITT) Population: A modified intent -to-treat 
population includes all subjects who are randomized, applied at least one dose of 
assigned product, and returned for at least one post -baseline evaluation visit.  
• Per Protocol (PP) Population: The PP population includes all  randomized subjects 
who met all inclusion/exclusion criteria, were compliant with the assigned study 
treatment, returned to the study site for the primary endpoint visit within the specified 
window (±2 days) OR discontinued from the study as a treatment f ailure, and did not 
have any major protocol violations .  Subjects who administered at least 50 % of IP, 
have at least one baseline and post baseline in clinic visit and did not have any major protocol violations.  
Subjects who discontinued early from the s tudy due to lack of treatment effect after completing 
at least eight weeks of treatment should be included in the mITT and PP population as treatment 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199945] in the primary endpoint 
analysis .  Subjects discontinued early for other reasons should be excluded from the PP 
population, but included in the mITT population.  
The results in the mITT population will be considered definitive for superiority of each active treatment to vehicle with those in the PP population considered supportive .  Safety analyses 
will be performed using the Safety population.  
14.2 Sample Size Determination  
Sample size of 10 4 randomized 1:1 Active to Vehicle based on 80% power to detect 33% IGA 
response in Active group versus 10% in the Vehicle group, with two- sided test and alpha =0.05.  
14.[ADDRESS_1199946] .  The variables for  safety endpoints are AEs, Local 
Application Site Reactions , vital signs measurements , clinical  chemistry and hematology .  AEs 
will be summarized based on the frequency of AEs and their severity for all treated subjects .  
All AEs will be coded using Medica l Dictionary for Regulatory Activities (MedDRA) and 
summarized by [CONTACT_1570] .  Data will be summarized using preferred term and primary 
system organ class.  
If a subject experiences multiple events that map to a single preferred term, the greatest seve rity 
and strongest Investigator assessment of relation to investigational product  will be assigned to 
the preferred term for the appropriate summaries .  Should an event have a missing severity or 
relationship, it will be classified as having the highest se verity and/or strongest relationship to 
investigational product . 
Summaries of AEs  will include any AEs reported beginning with the first dose of 
investigational product  on Day 1 .  The occurrence of adverse events will be summarized by 
 
[CONTACT_860792] r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199947]  will be generated .  All adv erse 
events reported will be listed for individual subjects showing both verbatim and preferred 
terms.  
Concomitant medications will be coded using the World Health Organization (WHO) dictionary .  Th is data will be summarized by [CONTACT_1570] .  Previous a nd concomitant 
medications will be presented in a data listing.  
 
14.3.3 Hypothesis  Testing / Assessment of Efficacy  
Further details of the planned statistical methods presented below will be provided in the study Statistical Analysis P lan (SAP) .  The purpose of the SAP is to further elaborate the statistical 
methods described in the protocol and describe analysis conventions to guide the statistical programming work.  Any changes to the final SAP will be documented .  Unless otherwise 
specified, the hyp othesis testing will be conducted by [CONTACT_860793] a two -sample 
two-sided test with a significance level of 0.050.  
The Evaluable P eriod for the outcome variables will be weeks 1, 4, 8 and 12. During each 
Evaluable Period an o rdinal value based on IGA, CEA, PSA  scores  will be collected .  The 
probability of improving will be the criteria to assess the superiority of the drug over the vehicle.  The null and alternative statistical hypotheses for the primary effectiveness endpoints are given by:  
(Ho) : The null hypothesis is that the probability of inproving (across the scale) with drug T 
(PrT)is less than or equal to the  probability of inproving with vehicle ( PrV)  
Ho: PrT ≤ PrV; PrT – PrV ≤ 0  
(Ha): The alternative hypothesis   is that the probabil ity of inproving with drug T ( PrT) is 
greater than t o the probability of inproving with vehicle ( PrV).  
Ha: PrT > PrV; PrT – PrV  > 0 
The change from baseline score of Skindex -16 will be compared among treatment at weeks 1, 
4, 8 and 12 by a repeated measure analysis.  
 
[IP_ADDRESS] Exploratory Endpoints  
IGA t reatment success, defined as “clear” or “almost clear” with a 2 -grade improvement in 
IGA score from baseline to the end of treatment.  
 CEA treatment success defines as “clear” or “almost clear” with a 2 -grade  improvement in 
CEA score from baseline to the end of treatment . 
 
14.3.4 Handling of Missing Values  & Sensitivity Analysis  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 56 of 71 
 
For the primary and secondary analysis  no missing values will be imputed .  A sensitivity 
analysis will be pe rformed by [CONTACT_448392] R egression Analysis using the following 
factors: treatment, age, gender, baseline IGA, baseline CEA, baseline PSA and the  results of 
the same variable from previous visits. 
 
14.3.5 Handling of Multiplicity  
No correction for multiplicity will be made.  
 
14.3.6 Primary Objective  
Assess the safety and tolerability of B244 applied twice daily to the face for 8 weeks in subjects with mild to moderate rosacea.  
 
14.3.7 Exploratory  Objectives  
To assess the efficacy of B244 in subjects with mild to moderate ros acea.  
• Proportion of subjects with IGA improvement at Week 8 relative to baseline . 
• Proportion of subjects with CEA improvement at Week 8 relative to baseline . 
• Change in IGA from Week 8 to Baseline .  
• Change in CEA from Week 8 to Baseline . 
• Proportion of Subjects with improvement in IGA or CEA at week 1, week 4, and week 12. 
• Change in Skindex 16 patient reported outcome from Baseline to week 1, week 4, 
week 8, and week 12.  
• Proportion of subjects with change in PSA at Week 1, Week 4, Week 8 and Week 12 
from  Baseline.  
• Evaluation of Telangiectasia score at Baseline/Day1 and week 8.  
 
14.3.7 Clinical Trial Protocol deviations  
At minimum, the following deviations will be summarized on the ITT population:  
 
• Inclusion or exclusion criteria not satisfied.  
• Deviations related to the investigational p roduct  administration  
• Not permitted concomitant medications.  
 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199948] be 
informed of their right to withdraw from the study at any time and for any reason.  
15.2 Other Required Approvals  
In addition to IRB/IEC approval, all other required approvals (e.g. approval from local Research and Development Board or Scientific Committee) required by [CONTACT_860794](s) .  It is the responsibility of the 
Investigator to notify the Sponsor and the CRO of the requirement of such approvals prior to participating  in the study.  
15.[ADDRESS_1199949] (or the subject’s acceptable representative), prior to inclusion in the trial, full and adequate verbal and written information regarding the objective a nd procedures of the trial and the possible risks involved.  The subjects 
must be informed about their right to withdraw from the trial at any time.  
Furthermore, it is the responsibility of the Investigator, or a person designated by [CONTACT_737], to obtain signed informed consent from each subject or the subject’s legally acceptable representative prior to inclusion in the trial .  The Investigator will retain the original 
of each subject's signed consent form.  
The informed consent form will be in compl iance with ICH GCP, local regulatory, and legal 
requirements .  The informed consent form used in this study, and any changes made during 
the course of the study, must be prospectively approved by [CONTACT_28150]/IEC and the Sponsor before use.  
15.[ADDRESS_1199950]’s right to protection against invasion of privacy .  Throughout this study, a subject’s source data  will only be linked 
to the Sponsor’s clinical study database or documentation via a unique identification number .  
As permitted by [CONTACT_1763], limited subject attributes, such as gender , 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  [ADDRESS_1199951]’s unique identification number. 
To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the 
Sponsor requires the Investigator to permit its monitor or designee’s moni tor, representatives 
from any regulatory authority (e.g., FDA), the Sponsor’s designated auditors, and the appropriate IRBs and IECs to review the subject’s original medical records (source data or documents), including, but not limited to, laboratory test  result reports, ECG reports, admission 
and discharge summaries for hospi[INVESTIGATOR_1684] a subject’s study participation, and autopsy reports. Access to a subject’s original medical records requires the specific authorization of the subject  as part of the informed consent process. 
Copi[INVESTIGATOR_1685] (i.e., subject name, address, and other identifier fields not collected on the s ubject’s CRF).  
15.[ADDRESS_1199952] (IRB) / Independent Ethics Committee (IEC)  
It is the responsibility of the Investigator to have prospective approval of the study protocol, protocol amendments, informed consent forms, and other relevant docum ents, (e.g., 
recruitment advertisements, subject’s diaries, if applicable) from the IRB/IEC .  All 
correspondence with the IRB/IEC will be retained in the Investigator File .  Copi[INVESTIGATOR_1099]/IEC 
approvals should be forwarded to the Sponsor or its designee.  
The only circumstance in which an amendment may be initiated prior to IRB/IEC approval is where the change is necessary to eliminate apparent immediate hazards to the subjects .  In case 
of such an event, the Investigator must notify the IRB/IEC and the Sponsor in writing 
immediately after the implementation.  
15.6 Publication  
No publication or disclosure of study results will be permitted, except under the terms and conditions of a separate, written agreement between Sponsor and the Investigator and/or the Investigator’s institution .  The Sponsor must have the opportunity to review and approve all 
proposed abstracts, manuscripts, or presentations regarding this study prior to submission for publication/presentation.  Any information identified by [CONTACT_154595].      
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 59 of 71 
 
16 ADMINISTRATIVE OBLIG ATIONS  
16.1 Curriculum Vitae  
An updated, signed, and dated copy of the curriculum vitae with the experience, qualification 
and training for each Investigator and/or Sub- Invest igator(s) will be provided to the Sponsor 
prior to the beginning of the Clinical Trial.  
16.2 Source Documentation Forms  
The Investigator/institution will permit study -related monitoring, audits/inspections, IRB/IEC 
review and regulatory inspection providi ng direct access to source documents, including all 
medical records or pertinent data relevant to the audit/inspection.  Source documents will represent a record of the raw data.  Source document templates may be provided by [CONTACT_860795] .  The source documents will become part of the subject's permanent 
medical record maintained by [CONTACT_977] .  If computerized systems are used to create, 
modify, maintain, archive, retrieve or transmit source data, they must comply with the applicable regulatory regulations and/or guidances (ex. 21 CFR Part 11 and 312). 
eCRFs will be used in this study .  eCRFs are required and should be completed for each subject 
participating in the study .  eCRFs will contain data captured from subject sourc e documents 
and results of laboratory tests .  In most cases, the source documents are contained in the 
subject’s chart at the hospi[INVESTIGATOR_54602]'s office .  In these cases, data collected on the 
CRFs must match the data in those charts .  Data must be  transcribed from the source documents 
(e.g. physical exam report, associated medical records, date and version of informed consent 
form) onto the CRF by [CONTACT_860796].  
Any corrections to entries made in the source docum ents must be dated, initialed and explained 
(if necessary) and should not obscure the original entry .  The Investigator has ultimate 
responsibility for the accuracy, authenticity, and timely collection and reporting of all clinical, safety, and laboratory data entered on the CRFs and any other data collection forms.  
Investigator will sign eCRFs electronically after completion of data entry, to attest that the data 
contained on the CRFs is complete and accurate .  Completed eCRFs are the sole property of 
the Sponsor and should not be made available in any form to third parties, except for authorized 
representatives of the Sponsor or appropriate regulatory authorities, without written permission from the Sponsor. 
16.[ADDRESS_1199953] Retention  
To enable evaluations and/or audits from regulatory authorities or the Sponsor, the Investigator agrees to keep records, including the identity of all participating subjects (sufficient information to link records, e.g., CRFs and hospi[INVESTIGATOR_1097]), all ori ginal signed Informed 
Consent Forms, copi[INVESTIGATOR_4600], SAE forms, source documents, detailed records of drug disposition, and adequate documentation of relevant correspondence (e.g., letters, meeting minutes, telephone calls reports).  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 60 of 71 
 
The records will b e retained by [CONTACT_860797] (ICH), local regulations, or as specified in the Clinical Study Agreement, 
whichever is longer.  
If the Investigator becomes unable for any reason to continue to retai n study records for the 
required period (e.g., retirement, relocation), the Sponsor will be prospectively notified.  The study records must be transferred to a designee acceptable to the Sponsor, such as another Investigator, another institution, or to the  Sponsor .  The Investigator must obtain Sponsor’s 
written permission before disposing of any records, even if retention requirements have been met. 
[ADDRESS_1199954] 
confidence along with all information furnished by [CONTACT_276981].  Independent analyses and/or publication of these data by [CONTACT_10420]/her staff is not permitted without prior written consent of AOBiome.   
Any formal presentation or  publication of data from this trial will be considered as a joint 
publication by [CONTACT_737](s) and appropriate Sponsor personnel.  Authorship will be determined by [CONTACT_11402] .  Written permission to the Investigator will be contingent on 
the review by [CONTACT_860798].  In all cases, the parties agree to submit all manuscripts or abstracts to all other parties at least [ADDRESS_1199955] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_95351]/IEC and health authorities, where required, it cannot be 
implemented.  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 61 of 71 
 
19 CLINICAL TRIAL PROTO COL AMENDMENTS  
Any protocol amendments will be added as stand -alone documents.  In addition, any and all 
revisions dictated by [CONTACT_276990].  Each time a protoc ol is 
amended, a new amended version date will be added to the cover page.  
The Investigator should not implement any deviation from, or changes of the Clinical Trial 
Protocol without agreement by [CONTACT_679473]/favorable opi[INVESTIGATOR_5698]/EC of an amendment. The Investigator is expected to take any immediate action required for the safety of any participant included in this study, even if this action represents a deviation from the protocol. In such cases, the report ing 
requirements identified in Section [ADDRESS_1199956] full access to all data.  The Sponsor may use or exploit all the results at its own discretion, without any limitation to its property right (territory, field, continuance) .  The 
Sponsor shall be under no obligation to patent, develop, market or otherwise use the results of the Clinical Trial.  As the case may be, the Investigator and/or the Sub- Investiga tors shall 
provide all assistance required by [CONTACT_1034], at the Sponsor's expense, for obtaining and defending any patent, including signature [CONTACT_56538].  
[ADDRESS_1199957]’s  personal data and Investigator's personal data which may  be included in the 
Sponsor database shall be treated in compliance with all applicable laws and regulations;  
When archiving or processing personal data pertaining to the Investigator and/or to the subjects , the Sponsor shall take all appropriate measures to safeguard and prevent access to 
this data by [CONTACT_13159].  
22 SPONSOR AUDITS AND I NSPECTIONS BY [CONTACT_860799], Good Clinical Practice and applicable regulato ry requirements, the Investigator should permit auditing by [CONTACT_537360].  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 62 of 71 
 
The Investigator agrees to allow the auditors/inspectors to have direct access to his/her study 
records for re view, being understood that this personnel is bound by [CONTACT_56520], and 
as such will not disclose any personal identity or personal medical information.  
The Investigator will make every effort to help with the performance of the audits and 
inspections, giving access to all necessary facilities, data, and documents .  As soon as the 
Investigator is notified of a future inspection by [CONTACT_56521], he will inform the Sponsor and authorize the Sponsor to participate in this inspection.  
The co nfidentiality of the data verified and the protection of the subjects  should be respected 
during these inspections.  
Any result and information arising from the inspections by [CONTACT_56522].  
The Investigator shall take appropriate measures required by [CONTACT_179662].  
22.1 Quality Control (QC) and Quality Assurance (QA)  
22.1.[ADDRESS_1199958] periodic monitoring visits to ensure that the protocol and Good Clinical Practice (GCP) are being followed .  The 
Investigator/institution will allow the Sponsor’s monitors or designees a nd appropriate 
regulatory authorities direct access to source documents to perform this verification. 
The study site may also be subject to quality assurance audits performed by [CONTACT_613406], and/or revi ew by [CONTACT_1201]/IEC, and/or to 
inspection by [CONTACT_663224](s) and their relevant personnel are available during the monitoring visits and possible audits or inspections, and that sufficient time is devoted to the process.  
22.1.[ADDRESS_1199959]’s source documents .  In the event of a significant deviation, the site will notify the 
Sponsor or its designee (and IRB or IEC, as required) .  Significant deviations include, but are 
not limited to, those that involve fraud or misconduct, increase the health risk t o the subject, 
or confound interpretation of primary study assessments .  Deviations from the 
inclusion/exclusion criteria will not be permitted unless written approval by [CONTACT_860800].  Should other unexpected circumstances arise that will  require deviation from 
protocol -specified procedures, the Investigator will contact [CONTACT_860801].  
Site will be responsible for proper maintaining and filing of all PD  related documentation in 
the site files.  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 63 of 71 
 
22.2 Trial Discontinuation/Investigative Site Termination  
The Sponsor reserves the right to discontinue the trial prior to inclusion of the intended number 
of subjects.  
After such a decision, the Investigator must  contact [CONTACT_27936] a time 
period specified by [CONTACT_391807].  
 
22.2.1 Criteria for Premature Termination or Suspension of the Study  
The following criteria may result in either temporary suspension or early termination of the study:  
• New information regarding  the safety or efficacy of the investigational product  that 
indicates a change in the known risk/benefit profile for the compound, such that the 
risk/benefit is no longer accepta ble for subjects participating in the study.  
• Significant violation of GCP that compromises the ability to achieve the primary study 
objectives or compromises subject safety.  
The Sponsor reserves the right to discontinue the trial for other valid administra tive reasons.  
 
22.2.2 Criteria for Premature Termination or Suspension of Investigational Sites  
A study site may be terminated prematurely or suspended if the site (including the Investigator) 
is found to be in significant violation of GCP, protocol, contr actual agreement, or is unable to 
ensure adequate performance of the study.  
 
22.2.3 Procedures for Premature Termination or Suspension of the Study or 
Investigational Site(s)  
In the event that the Sponsor and or a regulatory authority elects to terminate or suspend the study or the participation of an investigational site, a study -specific procedure for early 
termination or suspension will be provided by [CONTACT_1034]; the procedure will be followed by [CONTACT_860802].
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 64 of 71 
 
23 REFERENCES  
1. Prevalence and Incidence of Rosacea - rosecea statistics. 
http://www.whathealth.com/rosacea/incidence.html.  
2. Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, cellular, and molecular aspects in 
the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15(1):2- 11. 
doi:10.1038/jidsymp.2011.7. 
3. Weinkle AP, Doktor V, Emer J. Update on the management of rosacea. Clin Cosmet 
Investig Dermatol . 2015;8:159- 177. doi:10.2147/CCID.S58940.  
4. Blount BW, Pe lletier AL. Rosacea: a common, yet commonly overlooked, condition. Am 
Fam Physician. 2002;66(3):435- 440. http://www.ncbi.nlm.nih.gov/pubmed/12182520. 
Accessed October 26, 2016. 
5. Nally JB, Berson DS. Topi[INVESTIGATOR_860775]. J Drugs Dermatol . 2006;5(1):23- 26. 
http://www.ncbi.nlm.nih.gov/pubmed/16468288. Accessed October 26, 2016. 
6. Lindow KB, Warren C. Understanding rosacea. A guide to facilitating care. Am J Nurs . 
2001;101(10):44- 51; quiz 52. http://www.ncbi.nlm.nih.gov/pubmed/11680344. Accessed 
October 26, 2016.  
7. Muto Y, Wang Z, Vanderberghe M, Two A, Gallo RL, Di Nardo A. Mast cells are key 
mediators of cathelicidin -initiated skin inflammation in rosacea. J Invest Dermatol . 
2014;134(11):2728- 2736. doi:10.1038/jid.2014.222. 
8. Vance, J. (1986). Demodicidosis – do Demodex mites cause disease? Curr Conc Skin 
Disorder, 10–18.  
9. Bonnar, E., Eustace, P. & Powell, F. C. (1993). The Demodex mite population in rosacea. 
J Am Acad Dermatol 28, 443–448).  
10. Karincaoglu Y, Bayram N, Aycan O, Esrefoglu M. The clinic al importance of Demodex 
folliculorum presenting with nonspecific facial signs and symptoms. J Dermatol 
2004;31:618- 26.) 
11. (Lacey N, Delaney S, Kavanagh K, Powell FC. Mite -related bacterial antigens stimulate 
inflammatory cells in rosacea.British Journal of Dermatology  2007;157:474- 481).  
12. Demodex folliculorum and Demodex brevis in cutaneous biopsies. Aylesworth R, Vance 
JC. J Am Acad Dermatol. 1982 Nov; 7(5):583- 9). 
13. Arp DJ, Sayavedra -Soto LA, Hommes NG (2002) Molecular biology and biochemistry of 
ammonia oxidation by [CONTACT_596933]. Arch Microbiol 178: 250- 255 
14. Chandran K, Stein LY, Klotz MG, van Loosdrecht MCM (2011) Nitrous oxide 
production by [CONTACT_276997] -oxidizing bacteria and implications for engineered 
nitrogen -removal systems. Biochem Soc Trans 39: 1832- 1837. 
15. Weller, R., Price, R. J., Ormerod, A. D., Benjamin, N., & Leifert, C. (2001). 
Antimicrobial effect of acidified nitrite on dermatophyte fungi, Candida and bacterial 
skin pathogens. Journal of Applied Microbiology, 90(4), 648- 652. 
16. Rico, J., Quiring, J., Hollenbach, S., Enloe, C., & Stasko, N. (2014, August). Phase 2 
study of efficacy and safety of SB204 in the treatment of acne vulgaris. In Journal Of 
Investigative Dermatology (Vol. 134, No. 8, pp. S8- S8). [ADDRESS_1199960], 9th Floor, Ne w 
York, NY [ZIP_CODE]- 1917 [LOCATION_003]: Nature Publishing Group. 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 65 of 71 
 
24 APPENDICES  
Appendix 1: Investigator Global  Assessment  (IGA)  
 
Score  Grade  Definition  
0 Clear  No inflammatory lesions present; at most, mild erythema  
[ADDRESS_1199961] Clear  Very mild erythema present .  Very  few small papules/pustules  
2 Mild  Mild erythema .  Several small papules/pustules  
3 Moderate  Moderate erythema .  Several small or large papules/pustules, and up to 2 
nodules  
4 Severe  Severe erythema .  Numerous small and/or large papules/pustules, up to 
several nodules  
 
  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 66 of 71 
 
Appendix 2: Clinician Erythema Assessment (CEA)  
 
 Score  Severity  Description  
[ADDRESS_1199962] clear, slight redness  
2 Mild   Mild erythema; definite redness  
3 Moderate  Moderate erythema; marked redness  
4 Severe  Severe erythema; fiery redness  
 
  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 67 of 71 
 
Appendix 3: Patient Self-Assessment  (PSA)  
 
Score  Severity  Description  
[ADDRESS_1199963] describes your rosacea -related facial redness RIGHT NOW . 
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 68 of 71 
 
Appendix 4:  Skindex 16  
 
 

 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 69 of 71 
 
 
 
 

 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 70 of 71 
 
Appendix 5: Fitzpatrick Skin Assessment  
Score   0 1 2 3 4 
 What is the 
natural color of 
your hair?  Sandy red  Blond  Chestnut, 
dark blond  Dark 
brown  Black  
 What is the eye 
color?  Light blue, 
Gray, 
Green  Blue, 
Gray, 
Green  Blue  Dark 
Brown  Brownish 
Black  
 What is the color 
of sun unexposed 
skin areas?  Reddish  Very pale  Pale with 
beige tint  Light 
brown  Dark 
brown  
 How many 
freckles on 
unexposed skin 
areas?  Many  Several  Few Incidental  None  
 What happens 
when you are in the sun TOO long without 
sunblock?  Painful 
redness, blistering, peeling  Blistering 
followed by [CONTACT_860803], 
sometimes followed by [CONTACT_860804] a problem  
 How well do you 
turn brown?  Hardly or 
not at all Light 
color tan  Reasonable 
tan Tan very 
easily  Turn dark 
very 
quickly  
 Do you turn 
brown within one day of sun 
exposure?  Never  Seldom  Sometimes  Often  Always  
 How does your 
face respond to 
the sun?  Very 
sensitive  Sensitive  Normal  Very 
resistant  Never 
had a 
problem  
 When did you last 
expose yourself to 
the sun or artificial sun 
treatments?  More than 
3 months ago 2-3 
month ago 1-2 months 
ago Less than 
1 month ago Less than 
2 weeks ago 
 Do you expose 
the area to be 
treated to the sun?  Never  Hardly 
ever Sometimes  Often  Always  
• 00-07 points = Skin type  I 
• 08-16 points = Skin type  II 
• 17-25 points = Skin type III 
• 25-30 points = Skin type  IV 
• 30-40 points = Skin type V & VI  
 
Protocol Numbe r: RB244 -001 
Version 4.0;  07 JAN 2019  
  
 
Confidential| RB244 -001| Version 4.0 Amendment | Date:  07 JAN 2019  Page 71 of 71 
 
Appendix 6:  Telangiectasia Assessment  
  
Score  Grade  Definition  
0 Clear  No telangiectasia  
1 Mild  Only few fine vessels discernible, involves 10% or less of the 
facial area  
2 Moderate  Multiple fine vessels and/or few large vessels discernible, 
involves > 10% - 30% of the facial area  
3 Severe  Many fine vessels and/or large vessels discernable, involves 
> 30% of the facial area  
 